The randomized placebo-phase design: Evaluation, interim monitoring and analysis by Shook, Stephanie Lauren
THE RANDOMIZED PLACEBO-PHASE DESIGN:
EVALUATION, INTERIM MONITORING AND
ANALYSIS
by
Stephanie Shook
B.S. in Mathematics,
University of Texas at Austin, 2006
Submitted to the Graduate Faculty of
the Department of Biostatistics in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
University of Pittsburgh
2010
UNIVERSITY OF PITTSBURGH
DEPARTMENT OF BIOSTATISTICS
This dissertation was presented
by
Stephanie L. Shook
It was defended on
July 29, 2010
and approved by
Dissertation Director:
Howard Rockette, Ph.D., Professor, Department of Biostatistics
Graduate School of Public Health, University of Pittsburgh
Committee Member:
Jong Jeong, Ph.D., Associate Professor, Department of Biostatistics
Graduate School of Public Health, University of Pittsburgh
Committee Member:
Abdus Wahed, Ph.D., Associate Professor, Department of Biostatistics
Graduate School of Public Health, University of Pittsburgh
Committee Member:
Steven Belle, Ph.D., Professor, Department of Epidemiology
Graduate School of Public Health, University of Pittsburgh
ii
THE RANDOMIZED PLACEBO-PHASE DESIGN: EVALUATION,
INTERIM MONITORING AND ANALYSIS
Stephanie Shook, PhD
University of Pittsburgh, 2010
The randomized placebo-phase design, also known as the randomized delayed-start design,
has been proposed as an approach to circumvent the reluctance of patients and physicians to
participate in trials with a placebo control. Although there is some practical appeal to the
design and it has been used in an increasing number of active and ongoing trials, there are
often overlooked issues relative to statistical power, estimating sample size and determining
plans for interim analysis that may limit its usefulness. We developed a general model for
describing the pattern of treatment response and based on the specified parameters of this
model, derive and compare different strategies for interim monitoring. In addition to statis-
tical power considerations, we also provide results from extensive simulations investigating
the robustness of the proposed procedures since the efficiency of the randomized placebo-
phase design is highly dependent on the assumptions made about the form of the alternative
hypotheses.
Public Health Relevance: The randomized clinical trial is the gold standard for evaluating
new medical treatments/public health interventions. Indiscriminate use of the RPPD may
result in failure to identify important new treatment/interventions because of low statistical
power.
Keywords: Randomized placebo-phase design, Delayed treatment, Statistical power, Clin-
ical trials, Interim monitoring.
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1.0 INTRODUCTION
Clinical trials for diseases in which there are no standard therapies and rare diseases in which
there isn’t a large population to sample from encounter problems [12]. Recruitment is one
major issue, especially for the randomized controlled trial [22]. The problem of recruitment
can be greater for trials with a placebo arm. Patients as well as doctors may not want to
participate in a trial in which they might receive a placebo rather than the actual treatment
particularly if they believe the treatment will be beneficial. Feldman et al [8] proposed a
study design, the randomized placebo-phase design (RPPD), to help increase recruitment
in trials with a placebo arm. There are two phases in this design; the first is similar to a
randomized clinical trial with one treatment arm and one placebo arm. In the second phase,
both arms receive treatment. The time to event for both groups is then analyzed.
The RPPD, as proposed by Feldman, uses standard survival analysis to compare two
treatment arms where the same treatment is received in both groups but there’s a delay in
its administration to one of the arms. The basic idea underlying this study design is that if a
treatment is actually effective, then patients who start sooner should also respond sooner [8].
Assuming time to improvement is generated from an exponential, Feldman defines a high,
moderate, intermediate and low level of potency to correspond to median times of response
of 7, 14, 42, and 150 days, respectively with corresponding hazards of 0.099, 0.050, 0.017
and 0.0046. Feldman assumes that the placebo has a hazard of 0.0023 which corresponds
to a median time to spontaneous response of 300 days. The hazard ratio for each treatment
hazard compared to the placebo hazard, from the greatest hazard to the smallest, is 43,
22, 7, and 2. Feldman then assumes statistical power for a limited number of scenarios
was estimated using simulations [8]. Another design in which both groups recieve treatment
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involving a delayed start in the active treatment group is called the randomized delayed-start
design (RDSD). This study design was created specifically for clinical trials for Alzheimer
disease [20] and has been used in trials for Parkinson’s disease [10,24,25]. Unlike the RPPD,
which as proposed by Feldman has a ”time to event” as the primary outcome, most of
the applications of the RDSD appear to have repeated continuous measures as the primary
outcome [8]. The motivation behind the RDSD isn’t to increase recruitment, rather it’s more
disease-specific. For diseases like Parkinson’s and Alzheimer disease, the treatments tend to
treat symptoms rather than the actual progression of the disease. The randomized placebo-
controlled clinical trial doesn’t attempt to distinguish between these two scenarios. Through
the incorporation of a delayed active treatment in the control arm, the RDSD attempts to
address this dilemma.
In the RDSD, there are two phases. In the first, the early-start arm receives treatment
and the delayed-start arm receives placebo. In the second phase, both arms receive treat-
ment. The purpose of the first phase is to confirm that the treatment has an effect on
symptoms. Therefore, the improvement experienced by the early-start group may be solely
due to treatment of the symptoms rather than treatment of the actual disease progression.
Distinguishing between these two possibilities is the reason for the second phase. At the end
of the second phase, both groups should be experiencing improvement; however the early
start group should be constantly better than the delayed start group. This is interpreted
to mean that the early-start group is experiencing neuroprotection while the benefits of the
delayed-start group could be due to the treatment of the symptoms (similar to the early-start
group in the first phase) [6]. If the delayed-start arm experiences the same improvement as
the early-start arm in the second phase then the improvement is viewed as purely symp-
tomatic. There are three different hypotheses that are tested to show that the treatment
is actually slowing disease progression. At the end of Phase I the slope estimates between
both arms are compared to show that a difference exists. The second compares the estimate
of change in both arms from baseline to the end of Phase II. Finally, the third hypothesis
tests noninferiority of the slope estimates between the groups for only Phase II. Significant
differences in favor of the early-start arm must be apparent in all three of these tests to
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declare the study positive. Repeated measures analysis, specifically a mixed models analysis
of covariance, is used to test the above hypotheses [10].
There are several criticisms of the RDSD. D’Agostino describe the decisions that must
be made when conducting a RDSD as compared with a randomized clinical trial, such as the
length of each of the phases, the number of repeated measures, multiple comparisons, the
statistical analysis and the handling of missing data [6]. Clarke’s critique focuses specifically
on flaws of the studies for Parkinson’s disease, such as clinically significant differences, gener-
alizability of study results, and a conflicting hypothesis by Shapira and Obeso [3,31], that any
early symptomatic therapy will be beneficial for treating the actual progression of the dis-
ease. Therefore, the early-start group is intrinsically better off than the delayed-start group.
Contrary to Clarke, Kieburtz thinks that the RDSD is well suited to test for neuroprotection
in Parkinson’s disease by eliminating the confounder, treatment of symptoms [15].
The RPPD and RDSD are similar in that both entail a delay in the active treatment
in the control arm. However, the RDSD attempts to relate the design more closely to a
hypothesized disease process and proposes multiple hypothesis tests (conducted at different
phases of the study) to assess disease progression. The RPPD analysis is more simplistic. Our
focus in the first several specific aims will be on the usefulness and limitations of the general
concept of a delayed active treatment serving as a control arm and given that emphasis the
less complex and, to some extent, more general RPPD appears to be a more reasonable
framework in which to investigate the problem. However, we will integrate aspects of the
RDSD approach when they appear appropriate.
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2.0 AIMS
To evaluate the RPPD, different scenarios regarding statistical power will be analyzed such
as the effects of the lag time (length of the first phase) and the length of the study. Statistical
power depends on α (the type I error rate), δ (effect size), length of follow-up, N (sample
size), the underlying distribution of response and the statistical test used. The statistical
power at the end of the trial also depends on the percentage of the length of Phase 1 as
compared with the total length of follow-up. In addition, the statistical power at different
time points in the follow-up period will depend on the extent to which the response is time
dependent.
Simulations will be used to investigate the statistical power as a function of α, δ, N
(the total sample size), length of follow-up, and the percentage of the length of Phase 1 as
compared with the total length of follow-up. This will be done using a proportional hazards
model with the time to event assuming first an exponential then a Weibull distribution.
However, since the nature of this design violates the proportional hazards assumption, an
investigation into the statistical power for alternative tests to the proportional hazards model
will also be done.
In addition, more appropriate methods of sample size estimation will be developed specif-
ically for this design since standard formulas tend to assume proportional hazards. This will
entail creating a general format for describing the pattern of response to therapy. The RPPD
assumes treatment effects that may not be reflected with some therapies. This new format
will allow flexibility to portray different types of treatments. In fact, various scenarios rep-
resenting different types of therapies will be used to illustrate the effect this format has on
statistical power and sample size when utilized under the RPPD. Finally, more appropriate
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methods of interim monitoring will be developed since the RPPD differs so much from a
randomized placebo-controlled clinical trial. With this complete evaluation, a set of condi-
tions will be made as to when it is feasible to use this study design and how it should be
monitored. In summary relative to the RPPD, we will:
1. Conduct simulations to determine the effect of length of follow-up and length of delay
in treatment on statistical power for selected sample size, Type I error and δ. We will
also determine the difference in sample size that is required for different lengths of
delay to have the same statistical power as the standard placebo-controlled clinical
trial. Simulations will be conducted for exponential and for Weibull distributed
outcomes using the proportional hazards model to perform the analysis.
2. The proportional hazards model was used for analysis to address Specific Aim 1 because
this was suggested in the paper by Feldman et al [8]. However, results of the RPPD
clearly violate the proportionality assumption if treatment is effective. Therefore, we
consider alternative methods to analyze the RPPD. Simulations will be conducted and
asymptotic relative efficiency calculations will be performed to compare results
obtained using this method to results obtained using the proportional hazards model.
3. Previous simulations of this design done by others have assumed a model in which the
hazards in the control group change instantaneously at the end of the delay period. We
developed a more general model which incorporates an additional delay time after an
active treatment is initiated as well as a gradual change in hazard once the effect is
manifested. In addition, the model incorporates a pattern of attenuation after
treatment is terminated. Although simulations were selectively done for Specific Aims 1
and 2 under the new model, our primary rationale for developing this more general
simulation framework was to provide a more robust framework to develop guidelines for
interim monitoring.
4. Strategies for interim monitoring for the RPPD have not been formulated with
consideration to the unique properties of the RPPD (e.g. tendency to lose power with
increased follow-up) or with the potential impact that complex patterns of time
dependent response may have on selecting an appropriate monitoring plan. The
recommended approaches in the standard placebo-controlled trial usually entails
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adjusting the Type I error with consideration being given to the number of planned
interim analysis, a decision on the rate of spending of the Type I error and a
recommendation to plan analyses to have approximately an equal number of events
between consecutive analyses. These strategies and formulations may not be
appropriate for the RPPD. Furthermore, unlike the RDSD, the RPPD does not
consider any underlying biological considerations about the type or pattern of response.
We developed strategies and provide interim monitoring rules within the framework of
the model developed for Specific Aim 3.
5. Standard sample size formulas were evaluated and compared with simulation results to
determine their accuracy. Procedures for estimating sample size will also be developed
that take into consideration specific interim monitoring plans.
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3.0 EVALUATING THE RANDOMIZED PLACEBO-PHASE DESIGN
3.1 DISTRIBUTIONAL PROPERTIES
3.1.1 Probability Density Function and Expected Time to Event
In this section we provide the formula for the probability density function and the expectation
of time to event in the two arms of a RPPD, designated as ”treatment” and ”control”. The
treatment arm receives the active treatment immediately while the control arm has a lag of
a set amount of time until it receives the treatment. Denote the hazards for the treatment
and placebo as by λ1 and λ0, respectively. Let ti be the corresponding time until event
or censoring time for the ith subject. Assuming that time to event follows an exponential
distribution, the probability density function of the treatment group is
f(t) = λ1e
−λ1t (3.1)
with expected value
E(t) =
1
λ1
(3.2)
The control group follows a piecewise exponential distribution with PDF
f(t) =


λ0e
−λ0tP1 0 ≤ t < tP1
λ1e
−λ0tP1e−λ1(t−tP1) tP1 ≤ t <∞
(3.3)
where tP1 is the time until active treatment is given, also the length of Phase I. The expected
value is
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Table 3.1: Comparison of E(t) between Equation and Simulation Results
Treatment Group E(t) Control Group E(t)
Hazard Ratio Equation 3.4 Simulation Equation 3.2 Simulation
22 20.00 20.01 73.47 73.48
7 58.82 59.13 107.89 107.68
4 111.11 110.64 152.83 155.44
2 217.39 217.29 245.41 254.69
Assuming a year study and a 60 day lag
E(t) =
∫
tλ0e
−λ0tP1dt+
∫
tλ1e
−λ0tP1e−λ1(t−tP1)
=
1
λ0
e−λ0tP1
(
tP1 − 1
λ0
)
+ etP1(λ0−λ1)e−λ1tP1
(
tP1 +
1
λ0
)
(3.4)
The expected values for the four treatment potency levels considered by Feldman et al
for both the treatment and control groups are given in table 3.1 assuming exponentially
distributed times to improvement with tP1 = 60 for a year-long study [8]. Table 3.1 also
compares these results against simulation results. Simulations were run with a study length
of one year and a lag time of 60 days. There were 500 trials simulated, each with a total
sample size of N = 100 (50/group). The agreement between actual and simulated values was
good. Therefore, our subsequent simulation studies will be based on 500 replications.
3.1.2 Expected Number of Events
In clinical trials using ”time to event” as the primary outcome, the sample size is usually
estimated based on the expected number of events. With the RPPD, the expected number
of events must be found separately for the treatment and control groups. Let n1 be the
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treatment group sample size and ts be the total study length. For the treatment group
assuming an exponential distribution,
E(events) = n1F (ts) = n1(1− e−λ1ts) (3.5)
Also, let n0 be the control group sample size and tP1 be the length of Phase I (before initiation
of treatment in the control group). For the control group,
E(events) = n0F (tP1) + n0S(tP1)F (ts − tP1)
= n0(1− e−λ0tP1) + n0e−λ0tP1(1− e−λ1(ts−tP1)) (3.6)
The results for each treatment hazard given n1 = n0 = 100, λ0 = 0.0023, tP1 = 60 days
for studies of length tS = 60, 180 and 365 days assuming exponential times to improvement
can be found in table 3.2. The table also compares these results to the simulation results
with the same parameter values. The results show that for the longer follow-up period, the
number of events in the two treatment groups is virtually the same. For a study of 2 months,
which is comparable to a randomized placebo-controlled trial since the treatment delay in
the control group is also 2 months, the difference between treatment arms in the expected
number of events is much larger than the 6 month and 1 year studies, especially for the
higher hazard ratios. This suggests that the groups will become more similar as the study
continues which will lower statistical power for longer lengths of follow-up.
3.2 COX PROPORTIONAL HAZARDS MODEL
In order to evaluate the RPPD, different scenarios were considered and assessed based on the
statistical power. We conducted 500 simulations for each scenario. The hazards being used
are those previously described and the times to improvement are exponentially distributed.
Treatments were compared using the Cox proportional hazards model [4] with α = 0.05.
The control group had a hazard rate of 0.0023 for the first time period, Phase I, and then
had a hazard rate equivalent to the active treatment arm.
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Table 3.2: Expected Number of Events Assuming an Exponential Distribution
Treatment Group Control Group
Length of Study Hazard Ratio Equation 3.5 Simulation Equation 3.6 Simulation
2 Months 22 95 96 13 13
7 64 64 13 13
4 42 42 13 13
2 25 25 13 14
6 Months 22 100 100 100 100
7 96 96 90 90
4 81 81 71 72
2 57 58 51 51
1 Year 22 100 100 100 100
7 100 100 100 100
4 96 97 94 95
2 81 82 79 79
By treatment group, hazard ratio and study length for a 60 day lag period
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Figure 3.1: Effect of length of follow-up for each hazard with a 60 day lag assuming expo-
nential times to improvement and a total sample size N=100.
Additional simulations were done using a Weibull distribution to investigate the robust-
ness of our conclusions to other underlying distributions. An additional potency level with
a hazard of 0.009 was created to be approximately halfway between the intermediate and
low levels due to the gap between intermediate and low. We designate this potency level as
modest. Also, the high and moderate levels produced similar results. Therefore, we do not
present the high potency level. For investigating the effect of length of follow-up and loss
of power due to delay in treatment, a total sample size of N=100 (50 per group) was used.
Increases in both the lag time and length of study are presented in units of a month (30
days).
3.2.1 Effect of Length of Follow-Up
Usually for a randomized clinical trial with a placebo arm, as the duration of the study
increases, the statistical power will also increase. However, this is not necessarily the case in
the RPPD. Figure 3.1 exhibits this trend. A lag time of 60 days was used for the treatment
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delay in the control group since this is the recommended lag by Feldman et al [8]. The
different study lengths that were used started at 60 days and increased up to one year. For
a study length of 60 days, the trial is a standard randomized clinical trial with a placebo
arm since the length of delay of the treatment in the control arm is equal to the length of
the study.
For the moderate potency level and this sample size, the statistical power is 99+% at
all time points. In fact, for this potency level at the end of the 60 day delay period, an
average of 48 (96%) events has occurred in the treatment group. For the intermediate level
of potency, all of the different study lengths had power of at least 80%. The modest level also
has reasonable power, at least 80%, for the 60 day trial length but there are large decreases
in statistical power as follow-up increases. The statistical power to detect low potency is low
and becomes even lower as the length of the study increases.
3.2.2 Loss of Power as a Function of Length of Delay in Treatment
The highest statistical power is achieved when the control arm does not receive any treat-
ment, which is not consistent with the concept of the RPPD. A 0 day lag is uninformative
since both arms would be receiving treatment for the same length of time. For simulations,
we assume that the length of the study is 365 days. The delay of 365 days is used as a
reference point since it represents a standard randomized clinical trial with a placebo arm.
The results are presented in Table 3.3. A delay of 0 provides an estimate of the Type I error
which is reasonably close to the nominal 0.05 level.
For the moderate potency level, the lag time has no effect on statistical power since the
hazard is so great that the majority of patients in the active arm responds in less than 30 days
and is sufficient to result in early rejection of the null hypothesis. Even with the intermediate
potency, the early responses in the active treatment group dominates the comparison except
for short lag periods. For the lower hazards, there is a clear decrease in statistical power as
the lag time decreases.
Another way to view the loss of power due to the length of delay of treatment in the
control arm is by the minimum hazard needed to achieve approximately 80% power when the
12
Table 3.3: Loss of Power due to Length of Treatment Delay
Hazard Ratio
Lag (days) 22 7 4 2
365 99+% 99+% 99+% 80.4%
330 99+% 99+% 99+% 76.8%
300 99+% 99+% 99+% 70.0%
270 99+% 99+% 99+% 65.0%
240 99+% 99+% 99+% 60.2%
210 99+% 99+% 99.6% 50.8%
180 99+% 99+% 98.4% 44.6%
150 99+% 99+% 93.8% 33.4%
120 99+% 99+% 85.8% 26.8%
90 99+% 99+% 77.8% 16.4%
60 99+% 92.6% 41.6% 12.2%
30 99+% 49.4% 21.2% 6.2%
0 5.6% 4.6% 5.2% 6.0%
For a year study assuming exponential
times to improvement with a total sample
size N=100 for each hazard ratio
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Figure 3.2: Treatment hazard required for approximately 80% statistical power for the given
lag time for a year study assuming exponential times to improvement with a total sample
size N=100.
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Table 3.4: Sample Size Required for 80% Statistical Power
Hazard Ratio 3 Month Study 6 Month Study 1 Year Study
22 10 10 10
7 44 62 64
4 114 198 258
2 600 1180 1580
For a 3 month, 6 month and 1 year study by each hazard ratio
assuming exponential times to improvement with a 60 day lag
time
sample size is held constant, as displayed in Figure 3.2. As shown in table 3.3 with N=100,
for a lag of one year (a pure control arm) the low potency level has approximately 80%
statistical power. For a lag of 30 days, a hazard 5 times larger than the low hazard, 10 times
larger than the placebo, is required to have 80% power. Consequently, for larger hazard
ratios, a shorter lag can be used and still have at least 80% power. It appears that a lag
period of 150 days or greater does not strongly affect the hazard required for approximately
80% statistical power.
3.2.3 Effect on Sample Size
With the RPPD, a larger sample size than the standard placebo controlled trial is needed
to compensate for the loss in statistical power compared to a randomized placebo-controlled
trial. The goal of the RPPD is to make recruiting easier so it is possible a larger sample size
may be reached.
We have demonstrated in Section 3.2.1 that with this study design the statistical power
may decrease with increasing follow-up. For longer studies, statistical power could be main-
tained by increasing sample size. With a 60 day delay period in the control arm, the sample
size needed to obtain approximately 80% power at 90, 180, and 365 days for the various
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Table 3.5: Total Sample Size Required for 80% Power for Given Lag
Hazard Ratio
Lag (days) 22 7 4 2
365 6 12 22 96
330 6 12 24 104
300 6 12 26 118
270 6 12 30 136
240 6 14 34 174
210 6 14 40 192
180 6 14 50 228
150 6 20 60 322
120 6 26 84 440
90 6 38 140 796
60 10 62 260 1520
30 30 200 840 5800
For a year study by each hazard
ratio assuming exponential times
to improvement
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Figure 3.3: The statistical power for each phase of the RPPD for a year study assuming
exponential times to improvement with a total sample size N=100. The first phase includes
all trials while the second phase only includes those trials not rejected in Phase I.
hazard rates are shown in table 3.4. Table 3.5 depicts the sample size needed for 80% power
when changing the lag period. As mentioned in the previous section, as the lag time in-
creases, the sample size decreases. It will reach a point, however, when an increase in lag
time will not substantially decrease the sample size required to maintain statistical power.
The increase in required sample size is substantial at lower potency levels.
As noted in section 3.2.2, it appears that shorter lag periods tend to have lower statistical
power. This raises the question as to how much statistical power is gained in Phase II.
Although in Phase II there is no difference in hazards in the two groups, imbalances in
events accumulated in Phase I may still result in a rejection rate higher than the α = 0.05
type I error rate. Assuming a year long study, N=100 and exponential times to improvement,
we vary the length of Phase I in Figure 3.3. We only show the modest and low hazards since
the moderate and intermediate hazards have high statistical power as previously shown.
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The first graph in Figure 3.3 shows the statistical power at the end of Phase I. The
power increases as the length of Phase I increases. This is to be expected since Phase I is
a randomized placebo-controlled clinical trial. The second graph in Figure 3.3 depicts the
statistical power at the end of the study, or the end of Phase II, for each length of Phase I
given that the trial was not significant in Phase I. This graph shows how much statistical
power is added in Phase II for various lengths of Phase I. There is some additional power to
be gained in Phase II, but it is very minimal. From Figure 3.3, when the length of Phase I
is 180 days assuming the low hazard, 62.2% reject in Phase I. Out of the remaining 37.8%
of the trials carried over to Phase II, 10.1% reject H0 which is greater than the type I error
of α = 0.05. Regardless, most of the statistical power for this design in found in Phase I.
3.2.4 Effect of Nonexponential Improvement Times
3.2.4.1 Distributional Properties Originally, all simulations were done assuming ex-
ponential time to event. Yet this assumption may not be satisfied for many types of disease
responses. To investigate the robustness of our results, we also assumed improvement times
followed a Weibull distribution. Specifically, we repeated the previously presented set of
simulations assuming a Weibull distribution with varying shape parameters, κ = 0.5, 0.75,
2.0, 3.0. Since the hazard function for the Weibull distribution, H(t) = depends on time,a
generalized form from the exponential, 1
λ
, was used for all calculations and simulations.
Therefore, we denote θ1 =
1
λ1
as the treatment hazard and θ0 =
1
λ0
as the baseline hazard.
The particular parameterization chosen corresponds with that of the Weibull function in R
Statistical Computing Software, the program used to run the simulations. The PDF of the
Weibull distribution is
f(t) =
κ
θκ1
tκ−1e
−
(
t
θ1
)κ
(3.7)
with expected value
E(t) = θ1Γ
(
1 +
1
κ
)
(3.8)
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The Weibull distribution is robust since it includes densities with decreasing (κ < 1) and
increasing (κ > 1). For κ = 1, the density reduces to an exponential (constant hazard) and
for κ = 3.6, the Weibull is approximately normally distributed. Similar to the exponential
distribution, the expected number of events are can be estimated in the two groups. For the
treatment group,
E(events) = n1F (ts) = n1(1− e−(λ1ts)κ) (3.9)
and for the control group,
E(events) = n0F (tP1) + n0S(tP1)F (ts − tP1)
= n0(1− e−(λ0tP1)κ) + n0e−(λ0tP1)κ(1− e−(λ1(ts−tP1))κ) (3.10)
Tables 3.6, 3.7 and 3.8 give the expected number of events for the Weibull distributed
times to response for studies of length 60 days, 6 months and 1 year, respectively, given κ =
0.5, 0.75, 1.0, 2.0, 3.0 with the same hazard ratios that were used for the exponential results.
The exponential results κ = 1 are included as a reference since the form of the Weibull varies
for κ < 1 (event rate decreases over time), κ = 1 (event rate is constant over time) and κ > 1
(event rate increases over time). The simulation results are very similar to those calculated
from equations 3.9 and 3.10, reinforcing the use of 500 replications for the simulation study.
3.2.4.2 Results In the simulation investigating the effect of length of follow-up (Fig-
ure 3.4), the Weibull distribution tends to have lower statistical power for the lower shape
parameters but higher power for the higher shape parameters. For higher hazards a large
number of events occur in Phase I and there are few patients at risk in Phase II. Therefore,
the power is close to 1.0 and no decrease occurs. For most of the remaining scenarios, there
is a pattern of power loss as follow-up increases. The exception to this occurs for high shape
parameter and low potency.
We also now highlight the pattern for these scenarios. Figure 3.5 plots only the low
hazard in regard to the effect of length of follow-up for each shape parameter. An increase in
statistical power is apparent for the high shape parameters (κ > 1) as follow-up is increased,
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Table 3.6: Number of Events Assuming a Weibull for 60 Day Study
Shape Hazard Treatment Group Control Group
Parameter Ratio Equation 3.9 Simulation Equation 3.10 Simulation
0.5 22 83 83 31 31
7 64 64 31 32
4 52 52 31 32
2 41 41 31 31
0.75 22 90 90 21 21
7 64 64 21 21
4 47 47 21 20
2 32 32 21 21
1.0 22 95 96 13 13
7 64 64 13 13
4 42 42 13 13
2 25 25 13 14
2.0 22 100 100 2 2
7 65 65 2 2
4 26 26 2 2
2 8 8 2 2
3.0 22 100 100 1 1
7 66 65 1 1
4 15 15 1 1
2 2 3 1 1
For selected values of the shape parameter (κ = 0.5, 0.75, 2.0 and 3.0) and
hazard ratio assuming a Weibull distribution for a 60 day study with a 60
day lag
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Table 3.7: Number of Events Assuming a Weibull for 6 Month Study
Shape Hazard Treatment Group Control Group
Parameter Ratio Equation 3.9 Simulation Equation 3.10 Simulation
0.5 22 96 95 95 95
7 83 83 84 84
4 73 73 76 77
2 60 60 68 68
0.75 22 100 100 99 99
7 91 91 86 86
4 77 77 73 73
2 59 59 59 59
1.0 22 100 100 100 100
7 96 96 90 90
4 81 81 71 72
2 57 58 51 51
2.0 22 100 100 100 100
7 100 100 99 99
4 94 94 71 71
2 51 50 29 29
3.0 22 100 100 100 100
7 100 100 100 100
4 99 99 74 74
2 45 45 17 17
For selected values of the shape parameter (κ = 0.5, 0.75, 2.0 and 3.0) and
hazard ratio assuming a Weibull distribution for a 6 month study with a 60
day lag
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Table 3.8: Number of Events Assuming a Weibull for 1 Year Study
Shape Hazard Treatment Group Control Group
Parameter Ratio Equation 3.9 Simulation Equation 3.10 Simulation
0.5 22 99 100 99 100
7 92 100 93 100
4 84 96 87 94
2 73 81 79 79
0.75 22 100 100 100 100
7 99 100 98 100
4 92 96 91 94
2 78 81 79 79
1.0 22 100 100 100 100
7 100 100 100 100
4 96 97 94 95
2 81 82 79 79
2.0 22 100 100 100 100
7 100 100 100 100
4 100 100 100 100
2 95 94 85 86
3.0 22 100 100 100 100
7 100 100 100 100
4 100 100 100 100
2 100 99 94 94
For selected values of the shape parameter (κ = 0.5, 0.75, 2.0 and 3.0) and
hazard ratio assuming a Weibull distribution for a 1 year study with a 60 day
lag
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Figure 3.4: The effect of length of follow-up with a 60 day lag and total sample size N=100
assuming times to response are distributed as a Weibull with a shape parameter a) κ = 0.5,
b) κ = 0.75 c) κ = 2.0, and d) κ = 3.0
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Figure 3.5: The effect of length of follow-up by shape parameter assuming times to response
are distributed as a Weibull for the low hazard with a 60 day lag and total sample size
N=100.
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however a slight decline is seen for the low shape parameters (κ < 1) over time and which is
very low for all study lengths considered.
Examination into why this combination results in increased statistical power with in-
creased follow-up is performed. Figure 3.6 looks at the probability of event when κ = 3 for
all hazards including the baseline hazard that the control group experiences. A shape pa-
rameter of 3 was chosen since this is where the increase in statistical power is most extreme
for the parameters examined. The higher hazards have an immediate high response rate
while the lower hazards experience a delay until events begin to occur which escalates over
time. Therefore, the initial low statistical power for the low hazard (λ1 = 0.0046) is due
to the lack of events in both groups early in the study. The statistical power dramatically
increases as more events begin to occur in the treatment group. This relates to the expected
number of events found in tables 3.6 and 3.7. For kappa = 3 with the low hazard, at 60 days
there are 2 events in the treatment group against 1 event in the control group while there
are 45 events in the treatment group at 180 days and only 17 in the control group.
Similar to the results observed for the exponential distribution, an increased length of
Phase I results in loss of statistical power which can be seen in table 3.9 except for high
hazards where most of the patients in the treatment group have an event in Phase I making
power close to 1.0. The lower shape parameters have lower power and a steeper decline
in power while the high shape parameters have higher statistical power and appear to be
less affected by the change in lag time. The lower power occurs because there are less
events in Phase I. The increase in required sample size to obtain approximately 80% power
continues to remain substantial at lower potency levels when data are generated from a
Weibull distribution. The increase in sample size is greater for lower values of the shape
parameters. These results are shown in table 3.10.
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Table 3.9: Loss of Power due to Lag Time Assuming a Weibull Distribution
Hazard Ratio
Shape Parameter Lag (days) 22 7 4 2
0.5 365 99+% 99.4% 82.2% 29.8%
300 99+% 90.8% 41.2% 9.2%
240 99+% 76.4% 33.2% 7.2%
180 99.8% 59.4% 18.6% 5.8%
120 98.0% 40.6% 9.8% 8.6%
60 85.0% 19.6% 4.6% 6.8%
0.75 365 99+% 99+% 98.4% 60.4%
300 99+% 99+% 95.4% 31.0%
240 99+% 99+% 88.2% 22.4%
180 99+% 99.2% 71.2% 10.4%
120 99+% 93.4% 46.0% 5.8%
60 99+% 62.0% 18.6% 6.0%
2.0 365 99+% 99+% 99+% 99+%
300 99+% 99+% 99+% 99+%
240 99+% 99+% 99+% 99+%
180 99+% 99+% 99+% 99+%
120 99+% 99+% 99+% 99.6%
60 99+% 99+% 99.8% 66.6%
3.0 365 99+% 99+% 99+% 99+%
300 99+% 99+% 99+% 99+%
240 99+% 99+% 99+% 99+%
180 99+% 99+% 99+% 99+%
120 99+% 99+% 99+% 99+%
60 99+% 99+% 99+% 96.6%
For a year study and N=100 by each hazard ratio
27
Table 3.10: Sample Size Required for 80% Power Assuming a Weibull Distribution
Shape Parameter Hazard Ratio 3 Month Study 6 Month Study 1 Year Study
0.5 22 70 84 90
7 340 590 800
4 1800 9400 > 10000
2 > 10000 > 10000 > 10000
0.75 22 22 24 24
7 92 126 162
4 260 540 880
2 2200 > 10000 > 10000
2.0 22 6 6 6
7 12 10 12
4 34 36 38
2 168 140 150
3.0 22 6 6 6
7 6 6 6
4 26 16 16
2 196 80 60
For studies of length tS = 60, 180 and 365 days with a 60 day lag for each shape
parameter κ by each hazard ratio
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3.3 ASSESSMENT OF THE METHOD OF ANALYSIS
3.3.1 Peto and Peto Generalized Wilcoxon Test
Another problematic area of the RPPD is that it violates the assumptions of the proportional
hazards model. Harrington and Fleming [11] devised the Gρ family of tests in which ρ = 0
reduces to the log rank test and ρ = 1 is equivalent to the generalized Wilcoxon test by Peto &
Peto [27]. In the case of no covariates, the Cox proportional hazards model corresponds to the
log-rank test. Lee, Desu and Gehan show that the Peto & Peto and Gehan generalizations
of the Wilcoxon test have more power than the log rank test when the hazard ratio is
nonconstant [21]. When no censoring is present, both generalizations of the Wilcoxon will
have the same results, however when the data are censored, the weight function used in
Gehan’s test depends on the censoring pattern [2, 27]. Therefore, the Peto & Peto test is
recommended for use with the RPPD since it does not depend on the censoring pattern.
The Peto & Peto test statistic in the context of the Gρ family of test statistics has weights
on each event of S(t) which is the Kaplan-Meier estimate of survival.
The previous types of simulation models are used to compare the statistical power be-
tween the Peto & Peto test and the Cox model or log rank test. Figure 3.7 shows the effect on
power of increasing the length of follow-up, which appears to be higher for the Peto & Peto
test as compared with the Cox model, illustrated in Figure 3.1. In fact, both the moderate
and intermediate potency levels achieve 99+% statistical power for all study durations. The
modest potency level also has higher power than the Cox model, however there’s not much
of a difference for the low potency level. The higher statistical power when using Peto &
Peto’s test compared to the Cox proportional hazards model is reflected in the results of a
statistical power comparison between various tests presented in Lee et al [21].
The Peto & Peto test also gives higher statistical power when increasing the lag time
as seen in table 3.11. The results were the same as the Cox model (3.3) for the moderate
hazard. For the intermediate hazard, the Peto & Peto test achieves at least 80% statistical
power for all lag times while the Cox model achieved this type of power for lags of 60 days
or greater. Whereas the Cox model achieved at least 80% power for lags of 120 days or
29
Figure 3.7: Effect of length of follow-up assuming exponential times to improvement when
using the Peto & Peto test
greater for the modest potency level, the Peto & Peto test achieves this for lags of 60 days
or greater. For both tests, the low potency level only achieves 80% power at a lag of year
which is compatible with a randomized placebo-controlled trial. It should be noted that the
lag of 0 days is included to assess the type I error.
The most apparent differences between the two models can be seen when comparing
the sample size required for 80% power which is given in table 3.12. The sample sizes for
the moderate potency level are the same for both models due to the high and immediate
response rate of this 22-fold hazard ratio. The remaining potency levels see a large decrease
in sample size when using the Peto & Peto model, with the difference increasing as the hazard
decreases. Furthermore, for a year-long study with the remaining three potency levels, the
sample size using the Peto & Peto test is about half of the Cox model.
30
Table 3.11: Loss of Power due to Lag Time for Each Hazard
Hazard Ratio
Lag (days) 22 7 4 2
365 99+% 99+% 99+% 80.0%
330 99+% 99+% 99+% 79.4%
300 99+% 99+% 99+% 70.8%
270 99+% 99+% 99+% 70.2%
240 99+% 99+% 99+% 68.0%
210 99+% 99+% 99+% 62.0%
180 99+% 99+% 99.8% 55.8%
150 99+% 99+% 98.8% 45.8%
120 99+% 99+% 98.6% 36.2%
90 99+% 99+% 91.4% 29.0%
60 99+% 99.6% 71.6% 19.0%
30 99+% 83.2% 31.0% 8.6%
0 5.4% 5.4% 6.6% 5.4%
For each hazard ratio assuming exponential
times to improvement for a year study and
total sample size N=100 using the Peto &
Peto test
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Table 3.12: Total Sample Size Required for 80% Power for Peto & Peto test
3 Month Study 6 Month Study 1 Year Study
Hazard Ratio P&P LR P&P LR P&P LR
22 10 10 10 10 10 10
7 32 44 34 62 36 64
4 96 114 118 198 126 258
2 540 600 670 1180 800 1580
For studies of length tS = 60, 180 and 365 days with a 60 day
lag assuming exponential times to improvement when using the
Peto & Peto test. P&P represents the sample size when the
Peto & Peto test is used while LR stands for the log rank test
or Cox model
3.3.2 Asymptotic Relative Efficiency
The previous section showed that the Peto & Peto test appears to achieve higher statistical
power than the log rank test, especially for lower hazard ratios and longer lengths of follow-
up. The asymptotic relative efficiency (ARE) is an appropriate way to compare the Peto
& Peto test and the log rank test for non-proportional hazards. Chen used the Pittman
efficiency to show that the Peto & Peto has higher ARE than the log rank test under the
scale family of alternatives which assumes non-proportional hazards [2]. The Pittman relative
efficiency as δ → 0 is [5]
lim
n→∞
n
n′
(3.11)
where n′ is the sample size for statistic V that provides the same statistical power as sample
size n does for statistic T. The RPPD, however, does not fall into the scale family but rather
the location family. Let V be the Peto & Peto test statistic and T be the log rank test
statistic. Table 3.13 provides the relative efficiency for T (log rank statistic) and V (Peto &
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Table 3.13: Relative Efficiency for Peto & Peto Test Against Log Rank Test
Power Hazard Ratio n’ n ARE
0.70 7 49 29 1.690
4 198 96 2.063
2 1300 600 2.167
1.5 4600 2400 1.917
1.2 31600 17000 1.859
0.80 7 64 36 1.778
4 258 126 2.048
2 1580 800 1.975
1.5 5400 2950 1.831
1.2 30000 16000 1.875
0.90 7 90 43 2.093
4 330 154 2.143
2 2150 1160 1.853
1.5 7500 4200 1.786
1.2 45400 25400 1.787
0.95 7 110 60 1.833
4 410 206 1.990
2 2100 1120 1.875
1.5 8200 4300 1.907
1.2 50800 24800 2.048
For increasing statistical power and decreas-
ing hazard ratios assuming exponential times
to improvement for a year study with a 60
day lag
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Peto statistic) for selected values of the hazard ratio assuming a 60 day lag for a year-long
study assuming exponential times to improvement and for statistical power ranging from 0.70
to 0.95. The treatment hazards that are examined in this table are those previously discussed
plus two additional hazards, λ1=0.00345 and 0.00276 corresponding to hazard ratios of 1.5
and 1.2, respectively. In all cases except the moderate hazard (the hazard ratio of 22), the
Peto & Peto test performs better than the log rank test. For the moderate hazard, a hazard
ratio of 22, both tests perform equally well. As the statistical power increases and for the
remaining lower hazards, δ → 0, the relative efficiency is in the range of 1.8-2.0 suggesting
that the Peto & Peto test is approximately twice as efficient as the log rank test under the
non-proportional hazards assumption built into the RPPD.
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4.0 DESIGN ISSUES
The RPPD creates several challenges when designing a study. Two of these challenges are
closely examined in this section. Due to the non-constant hazard ratio and the large increase
in sample size required to have the same statistical power compared to a randomized placebo-
controlled trial, sample size estimation becomes problematic. In addition to the hazard and
the length of the study, the length of Phase I needs to be taken into account when estimating
sample size.
Sample size also may depend on the interim monitoring scheme. Due to the decrease of
statistical power over time and the non-constant hazard ratio, standard approaches assuming
proportional hazards may not be applicable. Since ethical and cost considerations recom-
mend the use of interim monitoring in randomized clinical trials, an appropriate method
needs to be developed.
4.1 INTERIM MONITORING IGNORING MULTIPLE COMPARISONS
Having a delayed active treatment serving as a control arm usually leads to decreased statis-
tical power for increased follow-up which provides part of the motivation for a new interim
monitoring scheme. First, an investigation into the statistical power at different points
during the study needs to be performed before any monitoring schemes are suggested.
As an example, we provide a simplistic monitoring scheme for the RPPD with a 60 day
lag period assuming exponential times to response. In relation to the RDSD described in
the introduction, an analysis is performed at the end of Phase I and another at the end of
the study. We extend this so that three analyses are conducted during the duration of the
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Table 4.1: Comparison of statistical power for interim analysis ignoring multiple comparisons
to statistical power of the SSD
Final Analysis
Hazard Analysis 1 Analysis 2 Analysis 3 Power SSD
22 99+% - - 99+% 99+%
7 99+% - - 99+% 99.8%
4 92.8% 0.6% 0% 93.4% 71.6%
2 32.4% 6.0% 1.8% 40.2% 15.0%
Assuming exponential times to improvement for a RPPD with
a 60 day lag and total sample size N = 100
study. These analyses are conducted at the end of Phase I (60 days), 6 months and at the
end of the study (1 year). The first analysis includes all trials while the second includes all
trials not significant (p-value ≤ 0.05) in the first analysis. The final analysis included all
trials not significant in first and second analyses. For comparison purposes, we also present
the statistical power if analysis is only conducted at the end of the trial (i.e. single-stage
design, SSD).
Table 4.1 shows that the first analysis contains the majority of the statistical power. For
the higher hazard ratios, almost all of the patients in the treatment arm have an event by
the end of Phase I and thus the trial has power close to 1.0. Only for a hazard ratio as
low as 2.0 is there a relevant contribution to statistical power at later analyses. In fact, as
expected, the analysis at the end of Phase I has higher power than the SSD. Although, we
still need to address the elevated type I error due to multiple comparisons. The results in
table 4.1 suggest that interim monitoring for the RPPD includes an analysis defined by the
time at which Phase I ends as was seen in the RDSD approach.
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4.2 INTERIM MONITORING ISSUES SPECFIC TO THE RPPD
Certain aspects of the RPPD may create obstacles for the creation of an interim monitoring
plan. For most situations, the statistical power decreases as follow-up is increased. This is
due to the the hazard ratio of 1 that occurs during Phase II of the RPPD. Thus, the pattern
of the hazard ratio under the alternative hypothesis is unique, with the maximum hazard
ratio occuring during Phase I or into Phase II rather than at the end of the study. The
interim monitoring plan should account for this challenge by conducting an analysis when
this maximum hazard ratio occurs to achieve the greatest statistical power. Knowledge of
the mechanism of action of the treatment would be useful in overcoming this obstacle. For
instance, if the treatment is not effective immediately or it takes time to reach its full effect,
the maximum hazard ratio may occur well into Phase II rather than the end of Phase I.
The treatment may also attenuate before the end of the study, causing its hazard to become
that of a placebo. For this particular case, the control group, which is still on treatment,
may actually have a higher hazard than the treatment group, which has returned to the
baseline or placbeo hazard. An appropriate interim monitoring plan and study design needs
to account for these challenges in order to maintain the desired statistical power.
The previous section illustrated the statistical power for a very simplistic monitoring
scheme. This scheme, however, did not take the multiple comparisons into account, thereby
inflating the type I error. The monitoring plan will need to be able to maintain the appropri-
ate type I and type II error rates without drastically increasing the expected sample size in
addition to accounting for the pattern of the hazard ratio under the alternative hypothesis.
4.3 GENERAL SIMULATION MODEL
In practice, the statistical power of the RPPD is dependent on the pattern of the response
to the active treatment. Prior simulations, were based on the assumption that the effect
of the active treatment is immediate and lasts for the duration of the trial regardless of
whether or not the active treatment is maintained. We now introduce a more general format
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Figure 4.1: Depiction of the general simulation model and its various parameters
to characterize response to therapy that incorporates delay periods prior to the active treat-
ment having a full effect and permits a decline in treatment effectiveness after treatment is
discontinued. The parameters characterizing the response to active treatment are as follows:
λ0 = baseline/untreated hazard
S1 = slope between baseline and treatment hazards
S2 = slope of the decline between treatment and baseline hazards
λ1 = hazard associated with treatment
γ1 = lag until treatment is given
γ2 = lag before treatment has any effect
γ3 = time treatment effect is increasing
γ4 = time the full effect of treatment is sustained
γ5 = lag until effect of treatment begins to decline
γ6 = time the effect of treatment is declining
The baseline and treatment hazards, λ0 and λ1, respectively, will be as previously defined.
Both slopes, S1 and S2, are assumed to be linear and vary depending on the treatment hazard.
We recognize that a linear change in the hazard is not what is actually occurring but that
for time points in the transition periods the average hazard is more likely to be a summary
of a mixture of individuals, some of whom have experienced the effect of active treatment
and some who are still in the delay phase. The γ′is represent different time periods and, as
a group, characterize the hazard over time for each treatment. The parameter γ1 is part of
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the study design and for the RPPD as previously described, γ1 = 0 in the treatment group
and γ1 is the period of treatment delay in the control group. For the situation in which
the treatment effect attenuates before the study terminates, λ0 is also the hazard after the
treatment effect has diminshed in both arms. Figure 4.1 illustrates the time periods defined
by the parameters of this model. A few examples will be simulated to show how different
circumstances can affect the statistical power of the study. The effect of length of follow-
up and the sample size required for 80% power will be investigated. Since the length of
treatment delay has been incorporated into the general simulation model and its effects on
statistical power have already been illustrated, the loss of power due to the length of delay in
treatment will not be explored here. Since we have shown in section 3.3.1 that the generalized
Wilcoxon test by Peto and Peto [11, 27] has superior power and in section 3.3.2 that it it
more efficient than the log rank test, this test will be incorporated into the simulations for
the general simulation model.
4.3.1 Scenarios for the General Simulation Model
Three scenarios of the general simulation model are presented here. They are:
1. γ1 = 60 days, γ2 = 0 days, γ3 = 60 days, γ4 = 90 days, γ5 = 0 days, γ6 = 60 days
2. γ1 = 60 days, γ2 = 1 day, γ3 = 3 days, γ4 = 110 days, γ5 = 1 day, γ6 = 3 days
3. γ1 = 60 days, γ2 = 0 days, γ3 =30 days, γ4 = 30 days, γ5 = 0 days, γ6 = 30 days
4. γ1 = 60 days, γ2 = 0 days, γ3 =60 days, γ4 =maintained for remainder of study
All of the scenarios use a lag time of γ1 = 60 days until active treatment is initiated in
the control group since the effect of this parameter has been previously discussed. The first
scenario involves a long period of increasing and decreasing treatment effectiveness. The
treatment is effective immediately but takes 60 days to reach its full effect which lasts for 90
days. Then its effectiveness declines for 60 days and at this time the hazard returns to the
baseline value. For the second scenario, the treatment has a longer time period of full effect.
The treatment takes 1 day to become effective, however it takes 3 days to reach its full effect.
This effect lasts for 110 days, then after 1 day the effectiveness begins to decline. It takes
3 days to reach baseline. The third scenario involves the full effect of treatment lasting for
39
a short duration. The treatment is effective immediately; however it takes 30 days for it to
reach its full potential which lasts for only 30 days. It experiences 30 days of decline until
it reaches baseline. Finally, the last scenario has an immediate effect of treatment with 60
days until it reaches its full effect. The treatment is then maintained for the remainder of
the study at its full effect.
4.3.2 Results for the General Simulation Model
First, the effect of length of follow-up was examined. For the moderate hazard, the statistical
power remains 99+% regardless of the length of follow-up, the same result obtained for
previous simulations in section 3.2.1. The other potency levels experienced similar trends
to those using the basic RPPD but with a steeper decline in statistical power as length of
follow-up increases for scenarios 2 and 3. Particularly, the third scenario appears to have
somewhat less power than the other three which is due to the short period of maximum
treatment effectiveness. The fourth scenario doesn’t experience much change within each
hazard as the length of follow-up continues due to the maintenance of active treatment. The
first scenario experiences a different trend that has not yet been seen. The results are shown
in Figure 4.2.
The different trend for the first scenario is shown in Figure 4.3 by looking at the effect
of length of follow-up for only the modest hazard. Therefore, we repeated scenario 1 using a
Weibull time to event. Recall that in this scenario, there is a long period of time when the
treatment effect is increasing as well as a long decline in treatment effectiveness when it is
not maintained. This produces an increase in statistical power then a decrease as length of
follow-up increases. This trend is much more substantial and extreme for κ > 1. For κ ≤ 1,
an initial slight increase occurs, but generally experiences a decrease in statistical power over
time. This scenario is of practical importance since it provides a useful scenario where the
maximum statistical power occurs well after (90 days) the end of Phase I (60 days).
Table 4.2 displays the sample size needed to achieve approximately 80% statistical power.
The sample sizes required for the low potency level for trial lengths of 6 months and 1 year
are much higher for the general simulation model scenarios than the basic RPPD. This is
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Figure 4.2: Effect of length of follow-up for each general simulation model scenario assuming
exponential times to improvement for each hazard ratio.
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Figure 4.3: Effect of length of follow-up for the first general simulation model scenario (γ1
= 60, γ2=0, γ3=60, γ4=90, γ5=0, γ6=60) assuming Weibull times to improvement for the
4-fold hazard ratio by shape parameter.
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Table 4.2: Sample size required for approximately 80% statistical power for selected scenarios
from the general simulation model
Scenario Hazard Ratio 3 Month Study 6 Month Study 1 Year Study
1 22 16 14 16
7 48 50 56
4 124 168 218
2 760 1000 1460
2 22 10 10 10
7 34 38 40
4 96 176 198
2 540 2100 2400
3 22 12 14 14
7 50 92 100
4 140 440 530
2 800 3400 4200
4 22 16 14 16
7 48 48 52
4 124 158 170
2 760 960 1120
By selected hazard ratios and study lengths assuming an exponential dis-
tribution
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Table 4.3: Sample size required for approximately 80% statistical power for selected hazard
ratios, shape parameters and study lengths for general simulation model scenario 1
Study Length
Hazard Ratio κ 3 Months 6 Months 1 Year
22 0.5 34 36 38
0.75 20 20 20
1.0 16 14 16
2.0 6 6 6
3.0 6 6 6
7 0.5 74 92 98
0.75 50 66 72
1.0 48 50 56
2.0 46 18 21
3.0 70 10 10
4 0.5 160 220 220
0.75 140 204 204
1.0 124 168 218
2.0 220 80 180
3.0 630 62 276
2 0.5 370 780 770
0.75 460 1000 1160
1.0 760 1000 1460
2.0 5000 600 1800
3.0 > 10000 600 2700
Assuming Weibull distributed times to response
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due to the loss of statistical power as length of follow-up increases which is the most severe
for the low hazard. Similar to the prior simulations utlitizing the basic RPPD to investigate
sample size, an increase in sample size to maintain statistical power is required as length of
follow-up increases. The first and fourth scenarios have the same sample sizes for the 3 month
study and similar sample sizes for the 6 month study due to the first three parameters in the
general simulation model being identical since the study ends before the other parameters
take effect.
Since scenario 1 has such a different trend than the others, table 4.3 displays the sample
size required to acheive approximately 80% statistical power for each hazard ratio by shape
parameter for the Weibull distribution. Restricting our focus to the modest and low hazard
ratios and the shape parameters κ = 2 and κ=3, the 6 month study has a much lower
sample size than the 3 month and 1 year studies. This coincides with the results in Figure
4.3 where the highest statistical power is located between 150 and 180 days. The extremely
large sample size required for the low hazard and κ=3 reflects the very low statistical power
seen in Figure 4.3 for a 90 days study when N=100 and is due to the low number of events
as seen in Figure 3.6.
4.3.3 Interim Monitoring Scheme Ignoring Multiple Comparisons
We extend the previous simplistic monitoring scheme for several different scenarios within the
general simulation model framework as was done with the basic RPPD. Three analyses were
conducted during the duration of the study in a similar manner as previously discussed. The
times of the first and second analyses vary for each setting. Five settings were examined, all
of which assumed exponential times to improvement and incorporated the general simulation
model scenario 4 with either a 90 or 60 day lag. Recall that scenario 4 assumes an immediate
treatment effect, 60 days to reach full effect which is then maintained for the remainder of
study. Only the results for the modest and low hazard ratios are shown due to the high and
immediate response rate which results in very high statistical power at the first analysis for
the moderate and intermediate hazards.
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Table 4.4: Statistical power for a simplistic interim monitoring scheme for various general
simulation model scenarios ignoring multiple comparisons
Hazard γ1 = 60 days γ1 = 90 days
Ratio Analysis 60, 180 90, 210 120, 240 90, 210 120, 240
4 1 50.4% 68.6% 59.6% 80.6% 87.0%
2 37.9% 15.9% 11.9% 15.5% 26.2%
Final 5.2% 3.0% 0.6% 4.3% 0%
SSD 58.5% 58.5% 58.5% 85.6% 85.6%
2 1 12.8% 17.0% 19.0% 23.0 26.8%
2 7.2% 4.2% 3.6% 8.6% 6.4%
Final 2.6% 1.4% 0.8% 1.2% 1.0%
SSD 11.8% 11.8% 11.8% 21.6 21.6
Assuming exponential times to response and a modest hazard
(λ1 = 0.009) ignoring multiple comparisons. Each setting assumes
a year-long study under general simulation model scenario 4 with
the columns split to consider either a 60 or 90 day lag. Recall
the remaining parameters are γ2 = 0, γ3 = 60, γ4 = maintained.
The row below the settings lists the times of the first and second
analyses in days. The final analysis occurs at the end of the study.
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Table 4.4 shows that γ1 = 90 gives the highest statistical power for the first analysis
as well as for the SSD although the hazard ratio of 2 has very low power for all analysis
plans considered. The maximum statistical power occurs approximately one month after the
end of the lag period for both the 60 and 90 day lags. Similar to the basic RPPD with a
60 day lag, the first analysis provides the majority of the power out of the three analyses.
However, within the general model framework and for the specific parameters selected, we
obtain additional power in the second analysis.
We extended this example to the Weibull distribution since it has been shown that
Weibull times to response can have different trends than the exponential distribution. Here
we assess the same five scenarios assuming 4-fold hazard ratio, a year long study and N=100
but for Weibull distributed times to improvement with shape parameters of κ = 0.5 and
κ = 2.0. The trends for the Weibull with κ < 1 are comparable, likewise for κ > 1, so only
one κ was chosen to depict the general trends for each case.
For κ = 0.5 in table 4.5, it appears that hardly any information is contained in the last
two analyses, which varies from the exponential. Stopping early at the first analysis, results
in higher statistical power compared with the SSD. This is most likely due to the loss of
power as follow-up is increased, which is more severe for the lower shape parameters of the
Weibull. The statistical power when κ < 1 is very similar at the end of the lag and one
month later for both γ1 = 60 and γ1 = 90 days.
The shape parameter can change the results drastically. For κ = 2.0 in table 4.5, the
second analysis holds some, if not more, statitsical power than the first analysis due to
maximum hazard ratio occurring well after the end of the lag period. Hardly any power
comes from the final analysis, which is similar to the results for κ = 0.5. In fact, for the
scenarios where γ1 = 90 days, all 500 simulated trials rejected in either the first or second
analysis. Even though all of the trials reject by the final analysis, the SSD has statistical
power close to 1.0 due to the high number of events occurring in the treatment group. This
is the special case that was highlighted in section 3.2.4.2 involving the high shape parameter
and lower hazard ratio. The results from these tables suggest that the distribution of the
times to response as well as the pattern of effect expected by the active treatment are crucial
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Table 4.5: Statistical power for a simplistic interim monitoring scheme for various general
simulation model scenarios ignoring multiple comparisons
γ1 = 60 days γ1 = 90 days
κ Analysis 60, 180 90, 210 120, 240 90, 210 120, 240
0.5 1 56.8% 59.2% 50.0% 82.6% 78.4%
2 2.0% 0% 0.2% 0% 0%
Final 0.6% 0% 0% 0% 0%
SSD 43.0% 41.8% 39.8% 59.6% 63.0%
2.0 1 17.8% 41.6% 86.2% 35.6% 92.0%
2 81.8% 58.2% 13.6% 64.4% 8.0%
Final 0.4% 0.2% 0.2% - -
SSD 99+% 99.8% 99.8% 99+% 99+%
Assuming Weibull times to response with κ = 0.5, 0.75, 2.0, 3.0
and a modest hazard (λ1 = 0.009). Each scenario assumes a
year-long study. The columns are split into scenarios with a 60
or 90 day lag with remaining parameters: γ2 = 0, γ3 = 60, γ4 =
maintained. The row below the scenarios lists the times of the
first and second analyses in days. The final analysis occurs at
the end of the study.
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to the design of the study and need to be taken into account when planning a study in
addition to the parameters of the general simulation model.
4.4 STANDARD STOPPING RULES
Group sequential designs are used to monitor clinical trials as they progress. These designs
allow for early rejection of the null hypothesis. One type of design strategy is the α-spending
rate functions that allow significance testing throughout the study while keeping the type I
error fixed. Two commonly used methods are Pocock’s test and the O’Brien & Fleming test.
The hypothesis of interest is H0 :
λ1
λ0
= 1 against a two-sided alternative. When describing
the test notation, let α′ be the nominal significance level with α being the overall significance
level or type I error. The basic RPPD rather than the general simulation model will be used
for simplicity.
It has been shown that Peto & Peto’s test should be used in place of the log rank test
so the question now becomes whether this test can be used with group sequential designs,
specifically the Pocock and O’Brien & Fleming stopping rules. Peto & Peto’s generalization
of the Wilcoxon is approximately multivariate normal [7, 11, 14]. As previously described,
this test is a member of Harrington & Fleming’s Gρ family of test statistics (ρ = 1) thereby
making it a member of Fleming & Harrington’s Gρ,γ family of test statistics (ρ = 1, γ = 0)
[9, 11]. Demirhan & Bacahn (2005) show that this latter family of tests, Gρ,γ , can be used
with group sequential designs [7]. Thus, the Peto & Peto test will be used in conjunction
with standard stopping rules within the class of group sequential designs.
4.4.1 O’Brien and Fleming Stopping Rule
Assuming a two treatment study with arms represented as A and B, let Sk be the score
statistic and Ik = V̂ ar(Sk). This leads to the standardized statistic Zk =
Sk√
Ik
[13]. Let δ be
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Table 4.6: Statistical power at each analysis using the Peto & Peto test with the O’Brien &
Fleming stopping rule for the basic RPPD
Analysis 1 Analysis 2 Final Analysis
Hazard Ratio Power I1 Power I2 Power % Accepting H0 I3 SSD
22 99+% 6.71 - - - - - 99+%
7 98.4% 6.20 1.2% 8.20 0.4% 0% 8.30 99.8%
4 44.6% 5.11 22.2% 8.17 11.0% 22.2% 8.35 71.6%
2 1.6% 3.85 7.0% 7.52 6.6% 85.2% 8.33 15.0%
Assuming a 60 day lag and exponential distributed times to response with N=100.
The study is 1 year long with analyses conducted at 60 days, 180 days and 1 year.
the hazard ratio under HA. The information for δ required for the fixed sample test is:
If,2 =
[Φ−1(1− α
2
) + Φ−1(1− β)]2
δ2
(4.1)
making the final information level
IF = If,2RB(K,α, β) (4.2)
where RB(K,α, β) can be found in table 2.4 from Jennison & Turnball [13]. Each interim
analysis should be planned to produce information levels close to Ik = IF
(
k
K
)
, k = 1, . . . , K.
At each analysis, the null hypothesis will be rejected if
|Zk| ≥ CB(K,α)
√
K
k
, k = 1, . . . , K (4.3)
otherwise the study will continue. Jennison & Turnball have tabulated the critical value,
CB(K,α) in table 2.5 [13]. The type I error probability will be close to α as long as the infor-
mation levels I1, . . . , IK are approximately equally spaced. The power at the final analysis,
1− β, depends on the information at the final analysis IK .
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Assuming K = 3 analyses and α = 0.05, the nominal significance levels are α′1 = 0.0006,
α′2 = 0.014 and α
′
3 = 0.045. Simulations were performed to assess the statistical power using
O’Brien & Fleming’s stopping rule for the RPPD. Compared to table 4.1, this test has much
lower power for the first analysis, the loss being much more severe as the hazard decreases.
Futhermore, a larger percentage of trials fail to reject H0 for this stopping rule in the final
analysis. This is due to the test being more conservative for early analyses, saving the type
I error for the final analysis which for the RPPD, is a time point at which the number of
events in the two treatment arms are more similar.
There appears to be higher statistical power for the interim analyses compared to the
single-stage design since the attenuation of the treatment differences does not occur with
the earlier analyses. The difference in power increases as the hazard decreases. However,
the information is very similar for the last two analyses. This suggests a problem with the
locations of the analyses. Also due to the design of the study, differences between the arms
are apparent early in the study with the difference attenuating as the study continues. This
trend was seen when examining the effect of length of follow-up on statistical power. This
suggests that O’Brien & Fleming stopping rule may not be the most appropriate analysis to
be used since it is more conservative at the beginning of the study where the differences are
expected to exist.
4.4.2 Pocock Stopping Rule
Pocock’s test uses the same nominal significance level at each interim analysis, which differs
from the O’Brien & Fleming test. This, however, may lead to higher statistical power since
Pocock’s stopping rule is less conservative at the early analyses were in the RPPD, larger
differences in treatment groups are more likely to exist.
Here we use similar notation found in the previous section. The information for δ required
for the fixed sample test is the same as the O’Brien & Fleming stopping rule. The final
information level, however, differs from that used with O’Brien & Fleming stopping rule.
IF = If,2RP (K,α, β) (4.4)
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Table 4.7: Statistical power at each analysis using the Peto & Peto test with the Pocock
stopping rule for the basic RPPD
Analysis 1 Analysis 2 Final Analysis
Hazard Ratio Power I1 Power I2 Power % Accepting H0 I3 SSD
22 99+% 6.71 - - - - - 99+%
7 99.8% 6.22 0% 8.36 0% 0.2% 8.36 99.8%
4 84.6% 5.11 2.0% 8.23 0% 13.4% 8.38 71.6%
2 18.4% 3.82 4.0% 7.50 0% 77.6% 8.33 15.0%
Assuming a 60 day lag and exponential distributed times to response with N=100.
The study is 1 year long with analyses conducted at 60 days, 180 days and 1 year.
where RP (K,α, β) can be found in table 2.2 from Jennison & Turnball [13]. Similar to
O’Brien & Fleming stopping rule, each interim analysis should be planned to produce infor-
mation levels close to Ik = IF
(
k
K
)
.
At each analysis, the null hypothesis will be rejected if
|Zk| ≥ CP (K,α) (4.5)
otherwise the study will continue. Jennison & Turnball have tabulated the critical value,
CP (K,α) in table 2.1 [13]. This test works best when there are no more than 5 analyses
performed K ≤ 5 [13]. The type I error probability will be close to α so long as the
information levels I1, . . . , IK are approximately equally spaced. The power, 1− β, depends
on the information at the final analysis IK .
Again, assuming K = 3 analyses and α = 0.05, the nominal significance level for each
interim analysis is α′ = 0.022. Table 4.7 shows the results of simulations performed to assess
the statistical power of Pocock’s stopping rule. The Pocock stopping rule, similar to O’Brien
& Fleming stopping rule, results in higher statistical power compared to the SSD with the
same type of trend. The same issues found with the O’Brien & Fleming test involving
information levels are also found here. The Pocock stopping rule also experiences a decrease
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in statistical power compared to the simulations ignoring multiple comparisons, however the
loss of power experienced here is not as severe. The Pocock stopping rules allows for a higher
nominal significance level for the first analysis compared to the O’Brien & Fleming stopping
rules which explains the higher statistical power.
The information levels appear to still be a concern since they are not equally spaced. In
particular, the last two analyses have similar information levels which is to be expected since
the difference between the treatment arms attenuates after Phase I where the first analysis
takes place. Although simultaneous accrual is not realistic so an accrual pattern needs to be
built in. Accrual may also help to even out the information levels. However, if the accrual
phase is short compared to the length of follow-up there will still be effect of no accumulating
information for the final analyses.
4.4.3 Addition of Accrual
Simulations were conducted considering 6 months of uniform accrual for a year study with a
60 days lag using Pocock’s stopping rules with the Peto & Peto test. As before, the nominal
significance level will be α′ = 0.022 for an overall type I error of α = 0.05 with N=100.
Three methods of analyzing the patient accrual are considered. In Method I, when 30%
of the patients have experienced the lag, an analysis is conducted that includes all patients
enrolled at that time (even if they have not experienced all of Phase I) and patients who are
beyond Phase I. The second analysis is conducted once 60% of patients have experienced
Phase I (in a manner similar to the first analysis) and the final analysis includes all patients.
When simulations were run under H0 for the Peto & Peto test,
the type I error was 3.4% when using Pocock’s stopping rule. The results from these simu-
lations are found in table 4.8.
In contrast, Methods II and III attempt to focus on finding the maximum hazard ratio,
and in turn, the maximum statistical power. For Method II, when 30% of the patients
have experienced Phase I, an analysis is conducted that includes all patients enrolled at
that time even if they haven’t experienced all of Phase I but only up to the end of Phase
I; no information beyond Phase I is analyzed. The second analysis is conducted once 60%
53
Table 4.8: Interim monitoring using Pocock’s boundaries and the Peto & Peto test with
uniform patient accrual assuming a basic RPPD
Analysis 1 Analysis 2 Final Analysis
Hazard Ratio Power I1 Power I2 Power I3 Power
22 98.2% 4.70 1.4% 7.52 0% 8.26
7 76.6% 4.05 9.2% 6.98 0% 8.23
4 30.8% 3.27 13.4% 6.01 0% 8.28
2 6.2% 2.42 4.8% 4.67 0% 8.05
Assuming exponential times to response with a type I error of
α = 0.05 and N=100 for a study of length 1 year. When 30%
of the patients have experienced the lag, an analysis is conducted
that includes all patients enrolled at that time and patients who
are beyond the lag. The second analysis is conducted once 60% of
patients have experienced the lag (in a manner similar to the first
analysis) and the final analysis includes all patients enrolled.
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Table 4.9: Interim monitoring using Pocock’s boundaries and the Peto & Peto test with
uniform patient accrual assuming a basic RPPD
Analysis 1 Analysis 2 Final Analysis
Hazard Ratio Power I1 Power I2 Power I3 Power
22 99+% 4.23 - - - - 99+%
7 88.8% 3.39 5.4% 7.04 0% 8.27
4 44.6% 2.62 12.2% 6.04 0% 8.29
2 6.2% 1.90 5.2% 4.64 0% 8.05
Assuming exponential times to response with a type I error of
α = 0.05 and N=100 for a study of length 1 year. When 30%
of the patients have experienced the lag, an analysis is conducted
that includes all patients enrolled at that time (even if they haven’t
experienced the lag) but only up to the lag (no information beyond
the lag is analyzed so that the maximum hazard ratio can be found).
The second analysis is conducted once 60% of patients have expe-
rienced the lag (in a manner similar to the first analysis) and the
final analysis includes all patients enrolled.
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Table 4.10: Interim monitoring using Pocock’s boundaries and the Peto & Peto test with
uniform patient accrual assuming a basic RPPD
Analysis 1 Analysis 2 Final Analysis
Hazard Ratio Power I1 Power I2 Power I3 Power
22 99.8% 2.07 0.2% 4.88 - - 99+%
7 72.8% 1.84 18.2% 4.57 5.2% 8.28 96.2%
4 26.4% 1.50 21.4% 4.15% 12.6% 8.34 60.4%
2 4.6% 1.09 6.2% 3.33 3.4% 8.14 14.2%
Assuming exponential times to response with a type I error of α = 0.05
and N=100 for a study of length 1 year. When 30% of the patients
have experienced the lag, an analysis is conducted that includes only
those patients who have experienced the lag but only up to the lag.
The second analysis is conducted once 60% of patients have experi-
enced the lag (in a manner similar to the first analysis) and the final
analysis occurs once all patients have experienced the lag.
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of patients have experienced Phase I in a manner similar to the first analysis and the final
analysis occurs once all patients have experienced the lag. Table 4.9 shows the results
from these simulations which show higher statistical power for the intermediate and modest
hazards. The moderate hazard has statistical power close to 100% for both methods while the
low hazard has statistical power around 11.0% for both. These represent the two extremes.
The hazard ratio of 22, or the moderate hazard has so many immediate responses that the
accrual pattern does not affect the outcome of the test while the hazard ratio of 2, or the
low hazard, has so few events resulting in statistical power not much higher than the type I
error. When simulations were run under H0 for the Peto & Peto test, the type I error was
3.8% when using Pocock’s stopping rule and 4.0% for the SSD.
Method III only includes those who have experienced the lag in each analysis. The results
in table 4.10 show that the statistical power is similar, but slightly higher than Method II.
The information levels for this method appear to have a larger gap between the third and
final analyses, most likely due to the uneven proportions of sample size between each analysis.
Under H0, the statistical power is 3.8% for Method II and 4.4% for Method III.
In regard to the information levels for all tables, they appear to be more evenly spaced
than the previous simulations assuming simultaneous accrual, yet they are not equally spaced
as desired. The moderate hazard for all methods ocnsidered rejects H0 in the first or second
analysis so there are no information levels to compare. For the remaining hazards in tables
4.8 and 4.10, the information levels observe a larger gap between the second and third
interim analyses. This might be due to the fact that 40% of the patients instead of 30% as
in the first two analyses, reach the end of the Phase I for the last analysis. Regardless, a
longer accrual period paired with a longer follow-up period may result in non-accumulating
information levels for the last two analyses which can affect the type I error. Method II in
table 4.9 sees a larger gap between the first two analyses except for the low hazard which
has approximately equally spaced levels of information. Method II also appears to be more
affected by the attenuation of the treatment difference between both arms.
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4.5 AN APPROPRIATE MONITORING SCHEME
An important component of the design of a clinical trial is the strategy for interim monitoring.
Investigations in previous chapters demonstrate that many of the characteristics of the RPPD
create problems for some of the standard procedures. Specifically, rules such as the O’Brien
& Fleming are very conservative at early analyses and less conservative at later analyses.
However, for the RPPD under many scenarios, differences are expected early rather than
late. Thus, as our early simulations show, we may lose power to reject the large differences at
the beginning of the study and later, when the rejection criteria is less strict, the differences
in treatment groups has attenuated. The stopping rules introduced by Pocock spread the
type I error evenly across all analyses which is better suited for the RPPD since it is less
conservative at the beginning of the study.
As previously discussed, many interim procedures, including Pocock’s stopping rules,
suggest or even require approximately equal steps of ”information” between analyses. How-
ever, at the later stages of follow-up for the RPPD, there is little if any information being
added. The fact there is little or no information being added at the end of the trial raises
the question of the benefit of increased follow-up past the end of Phase I. Our previous
investigations have identified two possible reasons for continuing past Phase I:
1. A lag in the treatment effect results in the difference in events between the two groups
occurring at a later time than the end of Phase I
2. The time to event is nonexponential with an increasing hazard, resulting in expected
treatment differences to exist even after Phase I has ended.
The general simulation model took into account the lags in treatment effectiveness while
the increasing hazard was illustrated through the incorporation of times to response dis-
tributed as a Weibull with shape parameter κ > 1. The reasoning behind the increased
follow-up in Phase II is because of these two possibilities. Therefore, the pertient question
appears to be are there sufficient early failures to result in rejection of H0 prior to the at-
tenuation of differences which will occur at some point. The problem is that we don’t know
exactly where the point of expected maximum cumulative differences in events will occur.
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Therefore, we propose to conduct a study of length tS = γ1 + γ2. This allows the study
to end at the point where the expected maximum hazard ratio occurs as well as allowing
for a lag in treatment effectiveness portrayed in the general simulation model. Using the
fact that accrual is not simultaneous to our advantage, once 25%, 50%, 75% and 100% of
the total patients reach the time point tS an analysis is to be conducted. Since the effect
of attenuation in Phase II is reduced, the information levels is believed to be approximately
equally spaced. This type of analysis also allows for either the Pocock or O’Brien & Fleming
stopping rule to be used due to the accumulation of early events not being affected by the
attenuation of increased follow-up. The only issue that remains is choosing an appropriate
sample size to achieve (1− β) ∗ 100% statistical power.
4.6 SAMPLE SIZE ESTIMATION
Since the RPPD has non-proportional hazards that are built into the design of the study,
usual sample size formulas are often not applicable. For clinical trials in which time to event
is the primary outcome, sample size formulas typically estimate the number of required
events as a function of the ratio of the hazards in the two treatment arms. For example, to
obtain (1−β)% statistical power, the total number of required events D, can be found using
a standard sample size formula [28] known as Method A
D =
4(Zα + Zβ)
2
ln(∆)2
(4.6)
where ∆ = λ1
λ0
and Zα and Zβ are the normal quantiles for α and β. Although the equation
assumes an exponential distribution it is approximately valid for the Weibull distribution as
well [28]. Statistical power can be calculated from this equation by solving
Zβ =
√
Dln(∆)
2
− Z2α (4.7)
59
Table 4.11: Comparison between the number of events required for Method A (parametric
equation, 4.6) and Method B (non-parametric equation 4.9) for approximately 80% statistical
power
Equation
Hazard Method A Method B
0.05 1095 1100
0.017 1359 1365
0.009 1852 1858
0.0046 3803 3809
which can be substituted into
Power = Φ(−Zβ) (4.8)
to find the statistical power given D, α and ∆.
An alternative formula is sometimes used which is less dependent on distributional as-
sumptions and will be called Method B. Using the same parameters as before, let
D =
(Zα + Zβ)
2(∆ + 1)2
(∆− 1)2 (4.9)
This approach can also be formatted in terms of statistical power rather than sample size.
Table 4.11 compares the number of events required for approximately 80% statistical power
between the parametric equation (4.6), Method A, and the non-parametric equation (4.9),
Method B. The calculated values are extremely close for both equations so the parametric
equation will be used since the generation of the simulated data is parametric.
These formulas assume that the two treatment groups have constant (but different)
hazards, an assumption violated by the RPPD. We evaluated the formula using the average
hazard (weighted by the length of Phase I and Phase 2) in the control arm. All calculations
assume a type I error of α = 0.05. The number of events required for 80% statistical power
is found in table 4.12 for each of the treatment hazards assuming a study of length 365 days
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Table 4.12: Comparison of sample size for 80% statistical power between Method A and
simulation
Results
Hazard λ∗0 ∆ Formula Simulation
0.05 0.0422 1.18 864 10
0.017 0.0146 1.16 1075 64
0.009 0.0079 1.14 1531 258
0.0046 0.0042 1.10 3749 1518
Assuming a year study using the basic RPPD
with a 60 day lag by each hazard ratio using
the weighted average control group hazard to
calculate the hazard ratio
with a lag of 60 days. The baseline hazard λ0 is 0.0023. Similar results were found for
Weibull distributed times to response, but are not shown here. The calculated sample sizes
from the equation are much larger than those simulated. This suggests that the average
hazard ratio doesn’t account for the large difference occurring early in the study due to the
delay of active treatment in the control group. Consequently, a new method needs to be
found.
4.6.1 Simulation to Estimate Sample Size
For a conventional randomized placebo-controlled trial, once a test statistic is selected, we
select δM , the minimum clinically important difference, supplemented by α, β, whether the
hypothesis is one or two-sided and estimates of the variability of the summary statistic, to
obtain estimates of N. In reality, for many of these conventional trials, δM is not used because
of unrealistically large sample size requirements. Thus, there exists a difference δP that is
believed will actually occur and the the difference δ′ used in the study is selected between
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δM and δP i.e. δM < δ
′ ≤ δP . For example, if δM = 20% reduction in death but requires a
total sample size of N=4000 while an actual reduction of δP = 50% is expected to occur, a
feasible sample size may lead to a study being able to detect a δ′ = 30% reduction in death.
Our goal in this section is to discuss a reasonable procedure for obtaining sample size
with the RPPD. Again, this problem is more complicated than the conventional trials due
to
1. nonproportionality of the treatment effect
2. the additional parameter of a lag time in treatment effectiveness, and
3. the strong possibilty that increased follow-up decreases statistical power.
We handle (1) by conducting a variety of simulations for different scenarios. (2) and (3)
require additional decisions to be made in the design process such as the estimated length of
the delay in treatment effectiveness and the length of the study in proportion to the length
of Phase I. We suggest the following steps as a reasonable process to arrive at the sample
size.
1. Estimate the baseline hazard λ0
2. Specify the ”minimum clinical difference” and provide a sample size estimate NP for this
in a regular placebo-controlled trial. If this sample size is feasible continue to the next
step.
3. Decide what is the difference (δP ) and associated hazard (λ1) one expects to obtain based
on literature, pilot data or biological considerations. For the RPPD to be feasible, λ1
should be much greater than λ0 i.e. λ1  λ0.
4. The longest lag period that is ethical for the study needs to be determined. If longer
lags are deemed ethical then a randomized placebo-controlled study should be recon-
sidered. Otherwise compute the sample size required if the study had length of Phase
I γ1. Another situation that could arise indicating the use of the RPPD, is that it is
ethical to have a pure placebo arm, but it is believed that this will cause the accrual to
be dramatically reduced.
5. Estimate, from literature, pilot data or biological considerations, the delay in the treat-
ment effectiveness γ2. We recommend that the analysis be conducted at γ1 + γ2.
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Tables 4.13 - 4.19 provide estimates for the basic RPPD assuming exponentially dis-
tributed times to improvement with various values of the hazard ratio, length of follow-up
and length of Phase I. The Peto & Peto test is used to determine the sample size for approx-
imately 80% and 90% statistical power for different lengths of follow-up and Phase I. These
tables can be used to obtain a sample size estimate that will maintain power at the desired
effect.
It should also be noted that use of the RPPD requires a price to be paid in terms of a
decreased statistical power or an increased sample size. The percent increase in sample size
required is
NRPPD −NP
NP
∗ 100 (4.10)
The percent increase in sample size may really be less than this value if the RPPD increases
accrual.
The tables provided do include two parameters, γ1, γ2 of the general simulation model but
the time of increasing treatment effectiveness γ3 and any attenuation of treatment effects
have not been considered. In the case where more parameters of the general simulation
model are estimated or time to event is believed to be a Weibull distribution, then the same
approach can be used but tables analogous to 4.13 - 4.19 need to be generated.
4.7 IMPLEMENTATION OF THE RPPD
In this section, we provide a practical example to demonstrate how to design a study using the
RPPD. In particular, the sample size estimation procedure and interim monitoring scheme
previously discussed is utilized, explained and simulated to find statistical power under
various parameters associated with the RPPD such as the length of Phase I γ1, the lag in
treatment effectiveness γ2, the type I error α, the type II error β, the baseline hazard λ0,
the minimally clinical significant difference δM and its associated hazard λM , the expected
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Table 4.13: Total sample size estimation table with λ0 = 0.0023, λ1 = 0.0046
Length of Follow-Up
Power Lag 120 150 180 210 240 270 300 330 365
80% 30 2030 2200 2400 2600 2700 2700 2740 2780 2780
60 600 730 780 800 802 804 806 806 806
90 300 360 390 400 406 414 426 426 430
120 - 240 260 276 280 284 286 288 290
150 - - 190 196 210 216 220 222 224
180 - - - 160 170 178 188 192 192
210 - - - - 150 154 156 158 160
240 - - - - - 130 134 134 136
270 - - - - - - 120 123 124
300 - - - - - - - 118 118
330 - - - - - - - - 104
90% 30 2200 3000 3200 3340 3420 3510 3580 3620 3670
60 800 880 940 990 1038 1060 1090 1110 1140
90 440 476 500 524 550 572 594 600 604
120 - 300 330 354 380 400 404 406 408
150 - - 260 290 294 296 298 300 302
180 - - - 210 240 242 242 244 244
210 - - - - 182 206 218 228 234
240 - - - - - 178 194 196 198
270 - - - - - - 150 160 162
300 - - - - - - - 144 148
330 - - - - - - - - 140
Assuming exponential times to improvement to achieve 80% and 90% sta-
tistical power by the lag time and length of follow-up in days using the
Peto & Peto test
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Table 4.14: Total sample size estimation table with λ0 = 0.0023, λ1 = 0.009
Length of Follow-Up
Power Lag 120 150 180 210 240 270 300 330 365
80% 30 580 680 760 800 820 840 860 890 900
60 160 180 200 216 232 240 250 258 270
90 70 88 98 110 120 126 130 132 134
120 - 52 60 68 72 78 82 84 86
150 - - 40 46 52 58 60 62 64
180 - - - 36 40 46 46 46 46
210 - - - - 30 32 34 36 38
240 - - - - - 28 30 32 34
270 - - - - - - 26 26 28
300 - - - - - - - 26 26
330 - - - - - - - - 24
90% 30 660 900 980 1020 1070 1100 1120 1140 1160
60 200 230 260 280 300 320 330 340 340
90 100 110 126 150 158 164 170 174 180
120 - 72 80 86 90 100 108 116 116
150 - - 56 62 68 74 80 80 80
180 - - - 48 56 56 60 60 60
210 - - - - 40 44 48 50 52
240 - - - - - 38 42 42 44
270 - - - - - - 36 38 40
300 - - - - - - - 34 36
330 - - - - - - - - 32
Assuming exponential times to improvement to achieve 80% and 90%
statistical power by the lag time and length of follow-up in days using
the Peto & Peto test
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Table 4.15: Total sample size estimation table with λ0 = 0.002, λ1 = 0.004
Length of Follow-Up
Power Lag 120 150 180 210 240 270 300 330 365
80% 30 2600 2820 3160 3420 3580 3580 3580 3580 3580
60 720 740 880 920 952 980 1000 1024 1040
90 400 436 460 500 510 520 536 550 550
120 - 280 300 310 320 324 332 340 346
150 - - 220 230 238 246 260 264 270
180 - - - 180 190 196 204 212 214
210 - - - - 160 170 178 180 180
240 - - - - - 140 148 152 154
270 - - - - - - 128 136 136
300 - - - - - - - 122 128
330 - - - - - - - - 116
90% 30 3200 3420 3700 3840 4600 4600 4600 4600 4600
60 1000 1020 1100 1200 1290 1360 1380 1390 1390
90 500 560 600 620 630 660 700 720 730
120 - 350 390 410 432 442 450 660 668
150 - - 280 290 300 300 316 326 334
180 - - - 248 256 264 270 276 282
210 - - - - 210 230 240 246 250
240 - - - - - 190 198 206 212
270 - - - - - - 176 184 190
300 - - - - - - - 160 164
330 - - - - - - - - 154
Assuming exponential times to improvement to achieve 80% and 90% sta-
tistical power by the lag time and length of follow-up in days using the
Peto & Peto test
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Table 4.16: Total sample size estimation table with λ0 = 0.002, λ1 = 0.006
Length of Follow-Up
Power Lag 120 150 180 210 240 270 300 330 365
80% 30 770 830 860 888 900 906 912 916 920
60 230 240 252 276 290 298 298 298 298
90 124 138 142 144 150 158 160 162 162
120 - 94 98 104 110 110 110 110 110
150 - - 70 76 80 80 82 84 86
180 - - - 64 70 70 72 72 72
210 - - - - 58 60 62 62 62
240 - - - - - 52 52 56 56
270 - - - - - - 46 48 48
300 - - - - - - - 46 46
330 - - - - - - - - 44
90% 30 1080 1140 1180 1210 1232 1232 1234 1234 1236
60 320 332 344 356 366 384 400 416 416
90 180 190 192 194 198 202 204 204
120 - 106 122 130 140 148 154 154 154
150 - - 96 102 106 110 114 114 114
180 - - - 86 88 92 96 96 98
210 - - - - 70 76 80 82 84
240 - - - - - 56 57 57 58
270 - - - - - - 52 56 56
300 - - - - - - - 51 51
330 - - - - - - - - 51
Assuming exponential times to improvement to achieve 80% and 90% sta-
tistical power by the lag time and length of follow-up in days using the
Peto & Peto test
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Table 4.17: Total sample size estimation table with λ0 = 0.002, λ1 = 0.008
Length of Follow-Up
Power Lag 120 150 180 210 240 270 300 330 365
80% 30 380 420 440 440 450 460 460 460 460
60 120 134 140 142 142 144 146 148 149
90 70 76 80 80 80 82 84 84 84
120 - 49 52 54 56 58 59 60 60
150 - - 40 42 44 45 46 46 47
180 - - - 36 37 37 38 39 40
210 - - - - 30 32 34 35 36
240 - - - - - 30 31 32 33
270 - - - - - - 29 30 31
300 - - - - - - - 29 30
330 - - - - - - - - 28
90% 30 460 520 560 590 610 614 620 622 622
60 180 182 188 188 190 191 192 192 192
90 100 101 102 104 104 106 106 106 108
120 - 70 73 74 76 78 78 79 80
150 - - 58 60 60 60 62 62 63
180 - - - 44 48 50 51 52 54
210 - - - - 42 43 44 46 46
240 - - - - - 40 42 43 44
270 - - - - - - 38 40 42
300 - - - - - - - 34 36
330 - - - - - - - - 34
Assuming exponential times to improvement to achieve 80% and
90% statistical power by the lag time and length of follow-up in
days using the Peto & Peto test
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Table 4.18: Total sample size estimation table with λ0 = 0.002, λ1 = 0.0010
Length of Follow-Up
Power Lag 120 150 180 210 240 270 300 330 365
80% 30 240 254 260 264 270 270 272 272 272
60 80 82 84 86 88 89 90 90 92
90 48 50 52 54 54 56 56 56 56
120 - 33 34 36 38 38 38 38 38
150 - - 28 30 30 32 32 32 32
180 - - - 28 28 28 28 28 28
210 - - - - 24 24 24 24 25
240 - - - - - 22 22 24 24
270 - - - - - - 22 22 22
300 - - - - - - - 22 22
330 - - - - - - - - 22
90% 30 330 360 370 372 374 374 374 374 374
60 120 120 120 120 122 122 122 122 122
90 60 62 64 66 68 68 70 72 72
120 - 50 50 50 51 52 52 52 52
150 - - 36 38 40 42 42 42 42
180 - - - 34 34 36 36 36 36
210 - - - - 28 30 32 32 32
240 - - - - - 28 28 30 30
270 - - - - - - 26 28 28
300 - - - - - - - 26 27
330 - - - - - - - - 26
Assuming exponential times to improvement to achieve 80% and
90% statistical power by the lag time and length of follow-up in
days using the Peto & Peto test
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Table 4.19: Total sample size estimation table with λ0 = 0.002, λ1 = 0.012
Length of Follow-Up
Power Lag 120 150 180 210 240 270 300 330 365
80% 30 180 182 182 182 182 182 182 182 182
60 58 58 62 62 62 62 62 62 62
90 34 36 36 38 38 38 38 38 38
120 - 28 28 28 28 28 28 28 28
150 - - 24 24 24 24 24 24 24
180 - - - 21 21 22 22 22 22
210 - - - - 20 20 20 20 20
240 - - - - - 18 18 19 19
270 - - - - - - 18 18 18
300 - - - - - - - 18 18
330 - - - - - - - - 17
90% 30 216 232 244 244 244 246 246 246 246
60 80 80 80 80 82 82 82 82 82
90 50 50 50 50 50 50 50 50 50
120 - 35 36 36 36 36 38 38 38
150 - - 32 32 32 32 32 32 32
180 - - - 26 26 26 26 28 28
210 - - - - 24 26 26 26 26
240 - - - - - 24 24 24 24
270 - - - - - - 24 24 24
300 - - - - - - - 22 22
330 - - - - - - - - 22
Assuming exponential times to improvement to achieve 80% and
90% statistical power by the lag time and length of follow-up in
days using the Peto & Peto test
70
treatment difference to actually occur δP and its associated hazard λ1, the total sample
size of the randomized placebo-controlled trial NP and the total sample size of the RPPD
NRPPD.
We begin by following a similar procedure found in the previous section on sample size
estimation. When meeting with clinicians to design a study, first the baseline hazard λ0
needs to be specified. The minimum clinically significant difference δM and its associated
hazard relative to the baseline hazard λ1 also need to be determined. The sample size for
a 1 year study NY and a 6 month study NM should be calculated using equation 4.6 or 4.9
for specific values of α and β. If these sample sizes are feasible, then a randomized clinical
trial with a pure placebo arm could be conducted if desired. However, if the sample size
estimates are too large for the trial to be implemented then an RPPD will not be practical
since the sample size requirements will likely be even higher.
If it is deemed unethical to place patients in a pure placebo arm or if adequate accrual will
be difficult because of the presence of a placebo arm, then the RPPD could be considered.
The next question is to determine what difference δP is expected to actually occur with the
treatment. As previously stated, the difference used in the design of the study δ′ should be
such that δM < δ
′ ≤ δP . If δP is much larger than δM then we could consider running at a
higher difference than δM and still obtain a significant difference.
Note this is an important conceptual difference in the RPPD and the standard clinical
trial. In designing the standard trial, the investigators utilize the minimum clinically signifi-
cant difference. The RPPD is often applied in situations where it is expected that the event
rate without treatment is low and the expected effect of treatment is high. The loss of sta-
tistical power due to the shortened period of time when the two arms are treated differently,
is compensated for by a high difference in δ. However this is no longer the minimal clinically
significant difference.
A decision on the length of the delay in treatment in the control arm γ1 is the next step
to be taken. Usually ethical considerations will guide the decision-making process. Using
the same standard sample size equations as before, the sample size for a study of length γ1
can be determined. If this sample size is reasonable, theoretically a randomized clinical trial
with a pure placebo arm could be used but due to the long process of patient accrual, those
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in the placebo arm would need to wait a period of time until the study ends and the results
are analyzed before they can be given treatment while the RPPD would provide treatment
sooner.
The introduction of the general simulation model provides a framework to characterize
the various responses to therapy. Adding another parameter γ2 to take into account the
period of time until the treatment becomes effective will better estimate when the maximum
hazard ratio will occur. We assume that once the treatment takes effect there will not be
a period of time while it is increasing to its full effect i.e. it is fully effective immediately.
With the addition of γ2 the maximum difference between the two treatment arms will be at
time tS = γ1+ γ2. Using tables 4.13-4.19, the sample size NRPPD can be found given tS and
γ1 for either 80% or 90% statistical power assuming exponential times to improvement.
It is unlikely that knowledge of the exact value of γ2 exists so it should be noted that
a maximum value should be used. If the maximum difference between the groups occurs
before tS, there will still be sufficient power for an analysis conducted at tS by using the
appropriate sample size from the one of the tables. If too small a value for γ2 is chosen, the
analysis will take place before the maximum difference thus lowering statistical power.
Given that the study length tS, the treatment and baseline hazards, λ1 and λ0, respec-
tively, and the sample size NRPPD have been identified, the interim monitoring procedure
should be chosen. Assuming uniform accrual patterns, four analyses will be conducted once
25%, 50%, 75% and 100% of patients have completed the study however only the last two
procedures will be utilized here. Method I will not be examined due to the low statistical
power seen in the previous simulations. Recall that Method II includes the percentage of
patients (25%, 50%, 75% and 100%) who have completed the study plus any other enrolled
patients while Method III only incorporates the percentage that have completed the study.
Assume that the baseline hazard is λ0 = 0.0023 and a minimal clinically significant
difference is δM = 2. The required total sample size for a year study is NY = 64 and for a 6
month study is NM = 108. The treatment, however, is expected to have an actual difference
of δP = 4 with a hazard of λ1 = 0.009. Suppose it is deemed unethical to have a pure placebo
arm longer than 2 months so the RPPD with γ1 = 60 days has been chosen as the study
design. The total sample size NP is found to be NP = 126 for a study of length γ1 = 60.
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However, it is realized that the treatment usually doesn’t take effect until 2 months later
(γ2 = 60 days) so this sample size is no longer applicable. Using table 4.14 a total sample
size of NRPPD = 160 should result in 80% statistical power given tS = γ1 + γ2 = 120 days.
These NRPPD patients will be accrued assuming uniform accrual over a period of 6 months
or 180 days.
Both Pocock and O’Brien & Fleming’s stopping rules will be used to account for the
multiple comparisons. The desirability of not being conservative at early analyses observed
in table 4.7 is not applicable here. In that analysis, all patients entered at the same time
point and repeated analyses were done over time while the proposed monitoring procedure
eliminates the attenuation of treatment differences by stopping the study at the maximum
hazard ratio. The nominal significance level for Pocock’s stopping rule is α′ = 0.0182 while
the nominal significance levels for O’Brien & Fleming’s stopping rule are: α′1 = 0.00006,
α′2 = 0.00388, α
′
3 = 0.01838 and α
′
4 = 0.04116 [13]. Due to the inclusion of these group
sequential methods, the sample sizes need to be altered the maintain the type II error.
Using tables 2.2 and 2.4 from Jennison & Turnball (2000), the adjusted sample sizes for the
Pocock and O’Brien & Fleming stopping rules are
NPOC = NRPPD ∗RP (K,α, β) = 160 ∗ 1.202 = 194
NOBF = NRPPD ∗RB(K,α, β) = 160 ∗ 1.024 = 164
(4.11)
respectively where K = 4 is the maximum number of analyses to be conducted. Each interim
analysis should occur once N
K
patients have been accrued. This will not occur when using
Method II due to the fact that the third analysis will take place at approximately 255 days
into the study (average accrual time for the 75th percentile of NRPPR = 160 patients being
accrued for 6 months is 135 days being followed until the end of the study, tS = 120 days)
while the accrual has ended at 180 days. This means that the third and final analyses will
have the same sample size since all patients have been accrued before the third analysis. Not
all patients have completed the study for the third analysis, but are included. All patients
will have completed the study for the final analysis though. The results for Method II are
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Table 4.20: Interim monitoring using Pocock and O’Brien & Fleming (OBF) boundaries
Stopping Analysis 1 Analysis 2 Analysis 3 Final Analysis Overall
Rule Power I1 Power I2 Power I3 Power I4 Power
Pocock 28.8% 7.64 18.0% 9.98 20.4% 11.09 6.0% 11.29 73.2%
OBF 2.6% 6.89 17.6% 8.47 38.6% 9.41 14.4% 9.63 73.2%
Assuming uniform patient accrual for 6 months with exponential times to re-
sponse utilizing the Method II analysis plan and the Peto & Peto test with
λ0 = 0.0023 and λ1 = 0.009. The type I error is α = 0.05, the type II error is
β = 0.20 with NRPPD = 194 for the Pocock stopping rule and NRPPD = 164 for
the O’Brien & Fleming stopping rule assuming a study of length 4 months.
included in table 4.20 to illustrate that the type II error is no longer maintained which
can be seen with the low statistical power and similar information levels at the last two
analyses. Under H0, the type I error was 3.4% for Pocock’s boundary and 5.2% for O’Brien
& Fleming’s boundary.
Table 4.21 shows the statistical power and information level at each analysis using Pocock
and the O’Brien & Fleming boundaries for Method III. The information levels are approx-
imately equally spaced with approximately 80% statistical power, suggesting accurate type
I and type II errors. When simulations were run under H0 using the Peto & Peto test, the
type I error was 5.8% for Pocock’s boundary and 5.2% for O’Brien & Fleming’s boundary
with Method III. Our proposal is that interim analyses be conducted only at a time point in
the range of values where differences are likely to be maintained and the repeated analysis
is done based on the proportion of patients reaching that point as done in Method III. The
O’Brien & Fleming or the Pocock stopping rule are reasonable procedures to consider when
the sample size is adjusted to account for the group sequential method being implemented.
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Table 4.21: Interim monitoring using Pocock and O’Brien & Fleming (OBF) boundaries
Stopping Analysis 1 Analysis 2 Analysis 3 Final Analysis
Rule Power I1 Power I2 Power I3 Power I4 Power
Pocock 20.6% 3.00 27.2% 5.87 17.4% 8.63 15.2% 11.32 80.4%
OBF 1.0% 2.48 15.2% 4.94 36.4% 7.33 24.8% 9.70 77.4%
Assuming uniform patient accrual for 6 months with exponential times to
response utilizing the Method III analysis plan and the Peto & Peto test with
λ0 = 0.0023 and λ1 = 0.009. The type I error is α = 0.05, the type II error is
β = 0.20 with NRPPD = 194 for the Pocock stopping rule and NRPPD = 164
for the O’Brien & Fleming stopping rule assuming a study of length 4 months.
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5.0 CONCLUSIONS AND DISCUSSION
The RPPD may facilitate recruitment in trials with a placebo control arm. However, there
are several issues that should be carefully considered prior to implementing the RPPD. These
are as follows:
1. There can be a large loss in statistical power compared to the standard randomized
clinical trial with a ”true” placebo arm. This effect is particularly large if the delay
period for treatment in the control arm is short compared to the study length but may
not occur if the response rate is high in the treatment group.
2. The large loss of power may not occur if the response rate is very high in the active
treatment group. The hazard rates evaluated by Feldman et al [8] ranged from 2 (low
potency) to 43 (high potency). For many diseases, a response to treatment is not realistic.
Even if such high responses are reasonably expected to occur, it should be recognized
that is does not represent a δ corresponding to the minimal clinically significant difference
(the convention adapted in traditional design).
3. The statistical power may be highly dependent on whether there is a time-dependent
response to active treatment (e.g. delay in response after receiving treatment or atten-
uation of effect once treatment is discontinued). As part of the sensitivity analysis in
estimating the required sample size, simulations should be conducted considering the
possibility of a time-dependent response to active treatment.
4. For many of the possible scenarios that can occur, the RPPD loses statistical power as
the follow-up increases. Thus the standard approaches for interim monitoring are not
applicable if the analysis includes a large number of patients whose follow-up period is
in the range of expected power loss (Phase II).
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5. The design clearly violates the assumptions of the Cox proportional hazards model.
Alternative statistical tests may increase the statistical power. Our initial simulations
show that the generalization of the Wilcoxon test by Peto and Peto appears to have
greater statistical power than the Cox proportional hazards model suggested by Feldman
[8].
In addition to these concerns, the design issues of interim monitoring and sample size
are vital to the proper implementation of the RPPD. As mentioned in item 3 above, the
response to therapy may be time-dependent. A general simulation model was created as
a tool to identify an appropriate monitoring scheme and maximize the potential statistical
power of the study. This model takes into account the treatment delay period in the control
arm, the effectiveness of the treatment and its attenuation. This model is crucial when
executing the RPPD since the maximum hazard ratio will usually occur shortly after the
end of Phase I due to the delayed effect of treatment and the initiation of treatment in the
control group. A lag in the treatment effect could extend the expected time at which the
difference in treatment arms is likely to occur. These factors should be built into the design.
As suggested by Feldman et al [8], the RPPD should be used for studies of rare diseases
or diseases in which there is no standard therapy. Preferably, the treatment should be much
more effective than the comparison therapy to achieve at least 80% statistical power. Other
aspects of the RPPD such as the length of Phase I and the length of the study need to be
appropriate to maintain a feasible sample size since most of the information is contained in
the first phase of the design.
The non-proportionality of the hazards and the attenuation of the difference between
treatment arms, creates difficulty in choosing an appropriate monitoring scheme. The mon-
itoring scheme should allow for the advantages of using the RPPD, such as ethical concerns
and accrual difficulties, while maintaining the desired type I and type II errors with a feasible
sample size. The sample size estimation procedure uses standard formulas in conjunction
with simulation tables to ease the implementation of this design.
There are limitations to this monitoring procedure. First, the concept of a futility analysis
may be relevant. Under simultaneous accrual, a futility analysis is preferred so the trial can
be stopped if no early difference is detected since the difference only attenuates as the study
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progresses. However, ending the study at time point tS limits the need for a futility analysis.
Regardless, it may still need to be incorporated if no difference or a negative difference is seen
in an early analysis. A conditional power approach, particularly stochastic curtailment, can
be utilized ad hoc to predict the probability of rejecting H0 given the current data. It should
be noted that conditional power approaches can result in a decrease of statistical power,
particularly a trade-off between cost in power and gain with respect to sample size which
can be controlled by the choice of the stopping threshold [32]. This stopping threshold, the
value of the parameter of interest and ”optimal” information fraction used to calculate the
conditional power are all arbitrary choices that need to be made with this approach [33].
There are group sequential designs that provide a format to support early stopping under
H0, HA or both. We used the Pocock [29] and O’Brien & Fleming [23] stopping rules for
early rejection of H0. There are other types of α-spending methods, such as those developed
by Lan & DeMets [19], Wang & Tsiatis [34] and Kim & DeMets [16] among others, that
could also be incoporated. Pampallona & Tsiatis (1994) extended the methods of Wang &
Tsiatis (1987) to include early stopping for futility [26, 34]. These boundaries also include
as special cases, Pocock and O’Brien & Fleming stopping rules and thus should occur at
equally spaced information levels [26, 34]. Kittelson & Emerson (1999) created a unifying
family of group sequential tests encompassing the α-spending methods and Whitehead’s
treiangular test among others, that includes early stopping for efficacy and futility [17].
Whitehead’s triangular test and a similar type of test, the sequential probability ratio test
(SPRT), incorporate early stopping in favor of H0. These tests allow great flexibility in
the timing of the analyses without altering the statistical properties [30]. The SPRT has
parallel boundaries leading to a open continuation region while the triangular test, on the
other hand, has convergent boundaries. Initially, Whitehead’s triangular test appeared to
be sufficient for this design, however construction of the boundaries requires information
about the hazard ratio under the alternative hypothesis HA. Due to the non-proportionality
of the hazards built into the framework of the RPPD, this is difficult to specify. A larger
hazard ratio will lead to boundaries closer together while a small hazard ratio will lead
to boundaries that are further apart and hence more difficult to cross. Another dilemma
when using this design along with the boundaries constructed by Pampallona & Tsiatis is
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the assumption that HA : θ > 0 where θ = −ln
(
λ1
λ0
)
which corresponds to reducing the
number of events as in the case where the event is death or failure. Implementation of these
designs using HA : θ < 0 to correspond to the treatment increasing the number of events,
as is the case with the RPPD, causes difficulty with calculating the boundaries. The lower
and upper boundaries are reversed which changes the statistical properties of the test. It is
assumed that with algebraic manipulation, these boundaries could possibly be incorporated
into the RPPD, however the approach taken here successfully outlines a procedure that can
successfully be used to monitor the RPPD while maintaining the desired type I and type II
errors without large increases in sample size.
In addition to a stochastic curtailment procedure, a test of increasing hazard in the
treatment group could be conducted if no differences are apparent. To employ this test, we
can obtain maximum likelihood estimates of the shape parameter κ and test H0 : κ = 1 vs
HA : κ > 1. Cumulative differences in events of the two groups also could be investigated.
If there is no significant difference, no evidence of increasing hazards and no evidence of
increasing cumulative difference of events in the two groups, consideration should be given
to stopping the trial, except for possible continuation of toxicity monitoring. Again, this is
a process to be determined as the study is progressing.
Another limitation of this monitoring scheme is the additional parameters in the general
simulation model. Assuming maintenance of treatment, another parameter of interest is
γ3 that represents the time while the hazard is increasing from baseline to its full effect.
We did not include sample size estimation tables incorporating γ3 but simulations could be
performed to do so. In this case, there are two possible stopping points. One is having the
study end at time point tS = γ1 + γ2 + γ3, however results in table 4.4 suggest that when
γ1 = 60 days, γ2 = 0 and γ3 = 60 days the maximum hazard occurs at γ1 + γ2 +
1
2
γ3. As
previously mentioned, the maximum values for γ2 and γ3 should be used to ensure that the
analysis is conducted where the maximum difference between the treatment groups occurs
or shortly after rather than before this point. Simulations can be used to assess both stopping
points.
A final consideration is the fact that treatment may affect each patient differently. Thus,
the parameters γ1 and γ2 could vary by patient. This was not taken into account in any of
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the simulations but could affect the statistical power of the study. This is a valid concern in
all types of clinical trials, however the RPPD is more sensitive to these parameters than the
usual clinical trial.
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